A Novel Perfusion Imaging Strategy for the Ischaemic Limb by Bajwa, Adnan Ahmad
This electronic thesis or dissertation has been 











The copyright of this thesis rests with the author and no quotation from it or information derived from it 
may be published without proper acknowledgement. 
 
Take down policy 
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing 
details, and we will remove access to the work immediately and investigate your claim. 
END USER LICENCE AGREEMENT                                                                         
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 
International licence. https://creativecommons.org/licenses/by-nc-nd/4.0/ 
You are free to: 
 Share: to copy, distribute and transmit the work  
 
Under the following conditions: 
 Attribution: You must attribute the work in the manner specified by the author (but not in any 
way that suggests that they endorse you or your use of the work).  
 Non Commercial: You may not use this work for commercial purposes. 
 No Derivative Works - You may not alter, transform, or build upon this work. 
 
Any of these conditions can be waived if you receive permission from the author. Your fair dealings and 
















A Novel Perfusion Imaging 




Adnan Ahmad Bajwa 
 
 
Thesis submitted for the degree of 




Academic Department of Surgery 
King’s College London 
School of Medicine 
Cardiovascular Division 
St Thomas’ Hospital 
1
st
 Floor North Wing 
Westminster Bridge Road 
















Statement of originality 
The work contained in this thesis is my own original work, except where 
acknowledged in the text. 
 
Acknowledgments 
I would like to thank my supervisors, Mr Bijan Modarai and Professor Alberto 
Smith, for their unrivalled support and guidance throughout my research.  I am 
indebted to them for their advice and encouragement in pursuing an academic 
path and for the skills and expertise that I have gained.  They have shown true 
kindness and professionalism when I have needed it most, and encouraged me 
to achieve more than I could have ever imagined before starting on this journey.   
I am extremely grateful for the assistance, advice and guidance of our 
collaborators, Professor Eike Nagel and Dr Roman Wesolowski.  Their 
expertise in perfusion MRI was invaluable for this project.  Professor Nagel 
provided expert opinion on how to develop this project.  Roman, I am so 
grateful for the long days and nights you spent helping develop the different 
MRI sequences, and also you expertise in MATLAB to develop and write the 
analysis software.   
The staff in the Academic Department of Vascular Surgery were vital in helping 
me develop the project.  I am particularly indebted to Ashish Patel, Prakash 
Saha and Mohammad Ikram for answering my stupid questions and showing 
me the ropes in research.  I would also like to thank the Vascular Surgery Unit 
at Guy‟s & St Thomas‟ Hospital, for allowing me to recruit the patients under 
their care and for letting me continue my clinical training. 
 4 
I would like to thank the all the people who agreed to participate in this study, 
allowing me to search for the answers to an ever-increasing clinical problem. 
I am extremely grateful for the invaluable financial support from the British Heart 
Foundation and the Circulation Foundation, without whom this project would not 
have been possible. 
I would like to thank my parents for raising me and providing me an education 
that has allowed me to achieve so much more then I could have ever thought 
possible.  You raised 4 boys, and showed them love, patience, kindness and 
the desire to never rest on our laurels.   
My wife Farrah, and the twins, Zakariya and Aleena have had to endure the 
biggest sacrifice.  They have had to do without me when I worked the long 
hours; they had to support each other and me.  This is all for you and without 
you this would mean nothing. 
Finally, this thesis is dedicated to my brother and best friend Nadim, who 
passed away at a young age from cardiovascular disease.  You showed me 
drive and determination; you showed my happiness and joy; you showed me 









Current assessment of peripheral arterial disease (PAD) is focused on 
delineating luminal narrowing or obstruction in the major lower limb blood 
vessels. The imaging modalities used do not provide information on the 
microcirculation or muscle perfusion in the affected limb, the most important 
determinants of limb salvage in patients with PAD. An objective, non-invasive 
method for measuring and mapping muscle perfusion would aid diagnosis in 
PAD. It would may also inform planning of revascularisation strategies and 
better determine success after revascularization, ultimately improving limb 
salvage. 
 
Blood Oxygenation Level Dependent Magnetic Resonance Imaging (BOLD-
MRI) is a technique that has been used to measure perfusion in the brain, 
kidneys and heart.  The utility of BOLD-MRI in the lower limb musculature has, 
to date, been limited by a lack of sensitivity and reproducibility.  
The present study aimed to develop BOLD-MRI as an objective and 
reproducible tool for measuring perfusion in the calf musculature. The calf was 
imaged at 3 Tesla in young healthy controls, age-matched controls, and 
patients with critical limb ischaemia (CLI). A cuff placed around the thigh was 
used during the scan to provoke hyperaemia. T2* Signal intensity time curves 
were generated for each muscle group and curve parameters, including signal 
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reduction during ischemia (SRi) and gradient during reactive hyperaemia 
(Grad). BOLD-MRI was also used to assess changes in perfusion following 
revascularization in CLI patients. Muscle biopsies, obtained at the level of 
BOLD-MRI measurement and from healthy proximal muscle of patients 
undergoing lower limb amputation were analysed for capillary:fibre (C:F) ratio.  
Good interuser and interscan reproducibility was found for Grad and SRi. The 
ischaemic limb had lower Grad and SRi compared with the contralateral 
asymptomatic limb, age-matched controls, and young controls. Successful 
revascularisation consistently resulted in significant improvement in both Grad 
and SRi. There was a significant correlation between C:F ratio in muscle 
biopsies from amputated limbs and Grad measured preoperatively at the 
corresponding level. 
These data suggest that BOLD-MRI holds promise as a reliable tool for 
assessing perfusion in the lower limb and may allow refinement of current 
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CHAPTER 1  
General Introduction 
1.1 Peripheral arterial disease 
1.1.1 Natural History, Epidemiology and Risk Factors  
Peripheral arterial disease (PAD), most commonly caused by atherosclerosis, is 
a condition that can lead to a severe restriction of blood flow in the arteries to 
the lower limb1 (Figure 1.1). Most individuals with PAD are asymptomatic2 with 
the remainder developing intermittent claudication (IC) or critical limb ischaemia 
(CLI).  The former refers to a condition characterised by pain in the limb that the 
patient experiences when walking, and is relieved by rest. The latter produces 
pain at rest, ulceration or gangrene and is associated with high morbidity and 
mortality.  Up to 25% of patients eventually lose a limb3.  Patients with PAD, 
irrespective of symptoms, have an increased risk of myocardial infarction and 
stroke, and are 6-times more likely to die within 10years4.  This condition 
represents a growing global healthcare problem, and is estimated to affect 27 
million people in Europe and North America5. The burden of PAD is likely to 
increase over the coming years as a result of ageing and increased life 
expectancy, improved treatment of coronary artery disease and increasing 










PAD is a progressive disease presenting with a spectrum of signs and 
symptoms.  Most individuals with PAD are asymptomatic2,7 with the remainder 
developing IC or CLI.  It is estimated that up to one third of patients with PAD 
present with IC.  Most patients with IC remain stable with only 5-10% 
deteriorating to CLI.  CLI is associated with poor outcomes with nearly a quarter 
of patients dead at 1 year and up to 30% of patients losing a limb1,3.   
Atherosclerosis affects any arterial territory, including the coronary and cerebral 
circulation, and therefore these patients also have increased risk of coronary 
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artery and cerebrovascular morbidity and mortality1,3–5,8,9.  Therefore patients 
with PAD, irrespective of symptoms, have an increased risk of myocardial 
infarction and stroke, and are 6-times more likely to die within 10years4.  The 













Several epidemiological studies have attempted to define the incidence and 
prevalence of PAD in the general population.  The difficulty has been in 
recruiting a true representative cohort of the general population to be able to 
define the incidence and prevalence.  It is estimated that the prevalence of 
asymptomatic PAD is in the region of 7-15%7,10, however, given the difficulties 
in investigating a truly representative population the incidence and prevalence 
is likely to be to higher.  One aspect that seems certain is that the prevalence of 
PAD increases with age (Figure 1.3). 
 
 
Figure 1.3:  Mean prevalence of intermittent claudication in large population based 







Atherosclerotic plaque formation in the arteries most commonly causes PAD.  
Factors that have been identified that accelerate plaque formation include older 
age (>40 years), hyperlipidaemia, hypertension, diabetes mellitus, race, gender, 
cigarette smoking and positive family history1,3,10,11 (Figure 1.4).  Addressing 
these risk factors plays an important role in the management of this group of 
patients and there is a low threshold for secondary prevention treatment 
including anti-platelet therapy, anti-hypertensive medications, smoking 
cessation, statin therapy and strict glycaemic control in diabetics.  Despite the 
acknowledged risks of cardiovascular morbidity and mortality in PAD patients 
the instigation of risk factor modification remains poor compared to patients with 
coronary or cerebrovascular disease12. 
1.1.2 Classification of PAD 
PAD is commonly categorised using the Fontaine13 or Rutherford14 
classifications (Table 1.1).  Both systems grade severity of disease based on 
symptoms.  The Rutherford classification was updated in 1997 to include criteria 
for designating clinical improvement which require an upward shift by at least 
one clinical category or in the case of tissue loss an improvement of at least 2 









Table 1.1:  Fontaine and Rutherford classification PAD
13,14
 
Fontaine  Rutherford   































Ischaemic Rest Pain 
Minor Tissue Loss 
Major Tissue Loss 
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1.1.3 Current Diagnostic Methods in PAD 
 A variety of simple diagnostic tests and imaging modalities are utilised in 
confirming the diagnosis of PAD and planning revascularisation. Ankle: Brachial 
pressure index (ABPI) is usually the first investigation performed to confirm the 
diagnosis and severity of PAD.  If clinical history and examination, along with a 
reduced ABPI suggests PAD, then commonly an imaging modality is utilised to 
confirm the diagnosis and also to plan intervention. 
Ankle: Brachial Pressure Index (ABPI)   
ABPI is currently the standard practice in the initial evaluation of patients with 
PAD and represents a ratio between the highest systolic pressure from either 
pedal arteries (dorsalis pedis or posterior tibial) and the highest systolic 
pressure from either arm measured at the brachial artery.  A continuous-wave 
Doppler ultrasound probe is used to measure the systolic pressure16.  The ABPI 
can also provide an indication of the severity of the PAD by virtue of the values 
obtained.  Furthermore, in cases where the diagnosis of PAD is unsure and 
other differentials are considered (such as spinal claudication or osteoarthritis) 
the ABPI can be a useful aid.  An ABPI of between 0.9-1.3 is deemed to be 
normal, whereas patients with IC typically have values of between 0.4-0.9.  
Patients with CLI typically have values <0.4.  An ABPI >1.3 is indicative of 
calcified, non-compressible arteries, commonly seen in patients with diabetes or 
chronic renal disease, and limits its use in these groups of patients1,3.  To 
overcome this limitation, toe: brachial pressure index (TBPI) has been used 
where pressures are measured in the digital arteries of the 1st or 2nd toe, with a 
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small cuff used on the proximal part of the toe.  A TBPI of >0.7 is considered 
normal, with values of <0.25 seen in patients with CLI1,3.  However, ABPI and 
TBPI provide an indication of the inflow to the limb, with no information on 
segmental muscle/tissue perfusion.  Nevertheless, ABPI has been shown to 
have a good sensitivity (80-95%) and specificity (95-100%) in detecting 
angiogram positive PAD1.   
A variety of imaging modalities are used to confirm the presence of PAD, 
evaluate its severity and to plan interventions. 
Duplex Ultrasonography 
Duplex Ultrasound uses a combination of B-mode ultrasound, to visualise 
structures, and colour Doppler ultrasound, to image flow.  Duplex is able to 
visualise and grade severity of arterial disease by assessing the haemodynamic 
changes in the peak systolic velocity (PSV) across a lesion1,3,17.  A PSV ratio is 
measured by comparing the velocities across a lesion to the PSV in the artery 
proximal to it.  The ratio can grade severity of arterial stenosis.  A PSV ratio 
greater than 2:1 indicates a >50% stenosis, greater than 4:1 a >75% stenosis 
and greater than 7:1 indicating a >90% stenosis17.   
Duplex is a non-invasive imaging modality, and is relatively cheap to perform, 
making it ideal as a first line modality for assessing severity of PAD.  It is 
however operator dependent and, for supra-inguinal lesions, it can be 
hampered by patient habitus and bowel gas.  Duplex ultrasound only images 
the major blood vessels in the lower limb, and its utility in assessing in very 
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distal tibial arteries and collaterals are limited.  Its use is also further limited in 
the presence of calcification where full examination of the arterial tree may not 
be possible.   Nevertheless, duplex is often used for decision-making prior to 
intervention and for surveillance after revascularisation of endovascular stents 
and bypass grafts.   
Computed Tomography Angiography 
Computed tomography angiography (CTA) provides high spatial resolution 
imaging (figure 1.5) of peripheral arteries and has a sensitivity and specificity of 
95% and 96% respectively18.  The rapid technical developments in CTA 
technology with multidetector scanners means that it is now possible to perform 
angiography of the whole peripheral arterial tree with short acquisition times, 
providing 3-dimensional (3D) high resolution images.  This makes CTA a very 
attractive modality to use to plan interventions and survey post-intervention 
patients.  Its availability 24 hours a day, 7 days a week makes it particularly 
useful in the acute settings, where experienced Duplex ultrasonography 




Figure 1.5:  Computed Tomography Angiogram (CTA) reconstruction in a patient with 
PAD demonstrates occlusion of the right common iliac, internal iliac and external iliac 
arteries (red dotted line).  This imaging can be used to plan revascularisation. 
 
CTA does require the administration of iodinated contrast agents with inherent 
risks of contrast-induced nephropathy (CIN) in high-risk patients (such as those 
with underlying renal impairment).  It is estimated that up to 17% of these high 
risk patients suffer with CIN after administration of iodinated contrast agents19.  
Although <1% of patients who develop CIN need renal replacement therapy17, 
there is a 5 fold increase in in-hospital mortality in patients with renal failure 
compared to those with patients who do not develop CIN (7% versus 34%)20.    
Another factor that needs to be considered when imaging with CTA is exposure 














7.47 mSv21, compared to the average annual background radiation exposure of 
between 2-3 mSv. In most patients with advanced PAD the life expectancy is 
significantly less than the latent period of a radiation-induced malignancy, 
however in younger patients this exposure risk is more pertinent and dosing 
should be minimised as much as possible. 
Calcification can make interpretation of CTA image difficult and the true extent 
of arterial disease can be difficult to quantify.  This becomes more problematic 
in the crural vessels of the leg. 
Magnetic Resonance Angiography 
Different techniques for magnetic resonance angiography (MRA) are available, 
but most commonly 3D contrast enhanced MRA is used for the assessment of 
PAD.  MRA has been shown to have a high sensitivity and specificity for the 
detection of arterial lesions (95% and 97% respectively)22, which is greater than 
CTA and duplex ultrasonography.  MRA is not affected by vessel calcification 
and is more accurate in assessing the crural vessels in the leg.  It avoids 
exposure to radiation and the gadolinium based contrast agents used have a 
lower risk of anaphylaxis compared to iodinated contrast agents17.  CIN is not 
an issue with MRA, however it is relatively contraindicated in patients with 
glomerular filtration rate of <30 ml/min due to the risk of nephrogenic systemic 
fibrosis (NSF), a condition characterised by fibrosis of the skin and internal 
organs resulting in contractures and reduced mobility23.  NSF is associated with 
increased long term morbidity and mortality24.   
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Not all patients are suitable for MRA, with the presence of metallic implants, 
such as cardiac pacemakers and cochlear implants contraindicated.  Even if the 
presence of metallic objects is not deemed a contraindication to MRA (for 
example MRA compatible arterial stents), artefacts can lead to signal loss if 
they are in close proximity to the arterial tree.   MRA does have the tendency to 
overestimate arterial stenosis, and venous contamination may make 
interpretation of extent of disease difficult, particularly below the knee17.  
Nevertheless the safety and high sensitivity and specificity means that the 
National Institute for Clinical Excellence (NICE) recommends that‟s patients with 
PAD being considered for intervention undergo MRA for planning 
revascularisation. 
Intra-Arterial Digital Subtraction Angiography 
The gold standard for imaging in PAD is still considered to be intra-arterial 
digital subtraction angiography (IADSA)1(Figure 1.6).  The added advantage of 
IADSA is the ability to perform endovascular revascularisation at the same time 
and the ability to measure pressure gradients allowing for assessment of 




Figure 1.6:  Inter-Arterial Digital Subtraction Angiogram (IADSA) in a patient showing a 
patent right common iliac (A), internal iliac (B) and external iliac (C) artery.  Occlusion of 
the left common iliac, internal iliac and external iliac arteries is seen (Red Dotted Line), 
with reconstitution of the left common femoral artery (D).  
 
IADSA is an invasive procedure, which is more costly than other imaging 
modalities and exposes the patient to both ionising radiation and iodinated 
contrast-agents.  Carbon dioxide has been used as an alternative contrast 
agent in patients with renal impairment to avoid CIN.  It is estimated that IADSA 
carries a 0.1% risk of severe reaction to iodinated contrast agents, a 0.7% risk 
of severe complications, and 0.16% mortality risk3.  IADSA images are also only 
2-Dimensional (2D) and can underestimate the severity of a lesion unless 
projections are undertaken in more then 1 plane, or pressure gradients 
measured.   
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1.1.4 Treatment of PAD 
Non-surgical Management 
The overriding management strategy in patients with PAD is the modification of 
risk factors associated with atherosclerosis.  These patients are at increased 
risk of morbidity and mortality from cardiovascular pathology affecting not only 
the peripheral circulation, but also the coronary and cerebral circulation12.  It is 
important to address risk factors such as smoking, hypertension, 
hyperlipidaemia and diabetes mellitus in this group of patients. 
Antiplatelet therapy, usually with aspirin and/or clopidogrel, is indicated in 
patients with PAD for secondary prevention from cardiovascular morbidity and 
mortality1,3.  The antithrombotic trialists‟ collaboration meta-analysis showed a 
23% reduction in serious vascular events in patients with PAD treated with 
antiplatelet therapy25.  Low dose aspirin (75-325mg) is most commonly used, as 
no benefit has been found with higher doses, but an increased risk of bleeding 
is associated26.  The CAPRIE trial investigated the cardiovascular outcomes 
showing a moderate benefit of clopidogrel over low dose aspirin, with a similar 
side effect profile for both medications27.  There is some emerging evidence for 
the combination of aspirin and clopidogrel in reducing cardiovascular morbidity 
and mortality, at the expense of an increase in bleeding risk28, however this 
benefit seems to only last for the short term and that extended duration dual 
anti-platelet therapy has no advantage over monotherapy29. 
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Smoking is perhaps the most important risk factor that needs addressing in 
patients with PAD.  The extent of tobacco intake correlates with incidence of 
PAD, severity of disease, lower limb amputation rates, occlusion of bypass 
grafts after revascularisation and mortality3,30–32.  Patients with PAD should be 
advised regarding the risks of continued smoking along with the benefits or 
giving up.  Patients enrolled on formal smoking cessation programmes along 
with nicotine replacement therapy are more likely to refrain from tobacco use in 
the long term with studies showing a 22% cessation rate out to 5 years, 
compared to 5% in groups not in a formal programme30, along with a significant 
survival benefit.  A Cochrane review concluded that the use of nicotine 
replacement therapy increased the odds of successfully stopping smoking by 
50-70%33. 
Patients with PAD should, along with an anti-platelet agent, be prescribed a 
statin.  The Heart Protection Study assessed the impact of statins on mortality 
and cardiovascular events and showed a significantly reduced all cause and 
cardiac mortality in patients taking statins, irrespective of their cholesterol 
level34.  More importantly the study found that in a subgroup of patients with 
PAD, a 22% reduction in major cardiovascular events.  A Cochrane review, 
including 18 randomised controlled trials with over 10,000 patients, scrutinised 
the effects of statins in PAD patients and found a significant reduction in 
cardiovascular events35.   
Attention needs to be paid to controlling blood pressure in patients with PAD.  
All drugs capable of reducing blood pressure should be considered in treating 
hypertension in theses patients.  The treatment goal for antihypertensive 
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therapy should aim for a blood pressure (BP) of below 140/90mmHg, and below 
130/80mmHg in patients with diabetes mellitus and/or renal insufficiency31.   
Diabetes mellitus increases the risk of PAD by approximately three- to four- 
fold3.  Diabetes is also associated with neuropathy and decreased resistance to 
infection, all of which lead to increased risk of tissue loss and ulceration in the 
limb and ultimately amputation.  It has not been determined as yet whether strict 
diabetic control yields improvement in outcomes such as limb salvage or 
freedom from repeated revascularisation in patients with PAD. Nevertheless, in 
diabetic patients, the haemoglobin A1c should be kept <7% and expert foot 
care is essential to minimise the risk of developing diabetic foot complications. 
The primary management strategy for PAD patients with IC is a supervised 
exercise program.  If an exercise programme is supervised (minimum 6 months) 
then an increase in walking time and distance, with lower severity claudication 
pain is seen in patient with IC compared to usual medical care or 
unsupervised/unstructured exercise1,3.  The main problem arises in the lack of 
availability of suitable supervised exercise programme for PAD patients to enrol 
in.  There is no role for exercise therapy in patients with CLI. These patients are 
at high risk of limb loss and therefore require urgent revascularisation 
Although the majority of non-surgical management if patients with PAD is aimed 
at addressing risk factors and reducing morbidity and mortality from secondary 
cardiovascular events, there are a range of „vasoactive‟ drugs now available for 
use in patients with IC to try to improve walking.  The two most common drugs 
used in patients with stable PAD are cilostazol and naftidrofuryl oxalate.  
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Cilostazol is a phosphodiesterase III inhibitor with vasodilator, metabolic and 
antiplatelet activity.  A meta-analysis of it‟s use in claudicants concluded 
cilostazol usage improved walking distance and quality of life compared to 
placebo36.  Naftidrofuryl oxalate is a 5-hydroxytryptamine antagonist, which is 
thought to improve muscle metabolism along with reducing platelet aggregation.  
In a meta-analysis it was shown that it improved walking distance by 26% 
compared to placebo alone37.  Currently NICE is the UK only recommends the 
use of naftidrofuryl oxalate in patients with IC. 
In patients with CLI the use of these vasoactive drugs is contraindicated, as 
they will not alter the outcome for these patients.  The only pharmacological 
therapy to have any benefit in CLI patients is prostanoids (such as iloprost).  A 
meta-analysis of the use of iloprost compared to placebo has shown significant 
benefit in ulcer healing, pain relief and in patients avoiding major amputation38.  
It has to be remembered that prostanoids are only indicated in CLI patients not 
suitable for revascularisation and is not available in all countries. 
More recently angiogenic cell therapies have been used to promote 
neovascularisation in an attempt to treat patients with PAD.  Early studies 
concentrated on the use of angiogenic proteins such as vascular endothelial 
growth factor39 and fibroblastic growth factor40, but more recently research 
involving stem cells41 and circulating monocytes42 have identified new avenues 
for promoting neovascularisation.  Cell therapy is, however, still in its infancy for 




The aim of surgical treatments for PAD is to improve blood flow to the affected 
limb.  This can be achieved by a minimally invasive endovascular approach, 
open surgery, or a „hybrid‟ approach incorporating both endovascular and open 
surgical techniques.  The Trans-Atlantic Inter-Society Consensus (TASC) 
document published guidelines for classifying the severity of PAD based on 
angiograms, along with recommendation on open surgical versus endovascular 
treatment strategies in 200043, with an update in 20073 (TASC II).  The 
principles behind which treatment strategy is considered is based on long term 
durability compared with relative risk of the procedure to patients.  The TASC 
classification is divided in to anatomical regions of the lower limb arterial 
circulation, with the classification for the aorto-iliac segment summarised in 
table 1.2 and for the femoral-popliteal segment in table 1.3.  TASC „A‟ lesions 
are considered to most amenable to treatment by endovascular techniques. 
TASC „B‟ lesion are also considered generally suited to an endovascular 
approach, unless open surgery is also required (such as femoral 
endarterectomy).  TASC ‟C‟ lesion should be treated with open surgical 
revascularisation, unless the risk to the patient is deemed to great, where 
endovascular treatment can be considered.  TASC „D‟ lesions do not yield 
adequate results from an endovascular method to justify then as first-line 
treatment.   
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Table 1.2:  TASC II classification of aorto-iliac disease 
CIA – common iliac artery; EIA – external iliac artery; CFA common femoral artery; IIA – internal 




Lesion Type       Characteristic 
A  Unilateral or bilateral CIA stenosis 
 Unilateral or bilateral single EIA stenosis <3cm 
B  Stenosis of infrarenal aorta <3cm 
 Unilateral CIA occlusion 
 Single/multiple stenosis 3-10cm involving EIA but not extending into CFA 
 Unilateral EIA occlusion not involving IIA or CFA 
C  Bilateral CIA occlusion 
 Bilateral EIA stenosis 3-10cm long but involving CFA 
 Unilateral EIA stenosis extending into CFA 
 Unilateral EIA occlusion involving IIA and/or CFA 
 Heavily calcified unilateral EIA occlusion with or without involvement of 
IIA and/or CFA 
D  Infrarenal aortic occlusion 
 Diffuse disease involving the aorta and both CIA/EIA 
 Diffuse multiple stenoses involving unilateral CIA, EIA and CFA 
 Unilateral occlusion of CIA and EIA or bilateral EIA occlusion 






Table 1.3:  TASC II classification of femoral-popliteal disease 




Lesion Type       Characteristic 
A  Single stenosis <10cm 
 Single occlusion <5cm 
B  Multiple lesions (stenosis or occlusions), each <5cm 
 Single stenosis or occlusion <15cm not involving below knee popliteal 
artery 
 Single or multiple lesions in the absence of continuous tibial vessels to 
improve inflow for a distal bypass 
 Heavily calcified occlusion <5cm 
 Single popliteal stenosis 
C  Multiple lesions totalling >15cm 
 Recurrent lesions needing treatment after 2 endovascular interventions 
D  Chronic total occlusions of CFA or SFA (>20cm involving the popliteal 
artery) 
 Chronic total occlusion of popliteal artery and trifurcation vessels 
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In formulating a management plan for patients with PAD multiple factors need to 
be considered not just the extent and anatomical location of disease, such as 
patient co-morbidity, life expectancy and local expertise in both open surgical 
and endovascular revascularisation. 
The division of the TASC classification into anatomical regions highlights it 
weakness as a method for determining revascularisation strategies as most 
patients with PAD do not present with arterial disease confined to a single 
anatomical region, but rather have disease affecting multiple levels of the 
arterial tree.  The principles behind revascularisation are to work from proximal 
to distal anatomical regions and to improve both the inflow and outflow of blood 
across a lesion in an attempt to improve the blood supply to the limb and the 
durability of the intervention.  For example, revascularising a tibial vessel in a 
patient with CLI is unlikely to successful if the femoral-popliteal segment 
proximally is significantly diseased, and distal to the revascularisation the artery 
is occluded.   
Blood supply below the knee is via 3 blood vessels, the anterior tibial artery, the 
peroneal artery and the posterior tibial artery.  When revascularising to below 
knee vessels, most commonly in the context of CLI, the artery with the least 
amount of disease and best continuous flow to the ankle and foot is usually 
chosen.  When the patient has tissue loss associated with their CLI, there are 
some clinicians who believe in targeted revascularisation to the blood vessel 
directly supplying the area of tissue loss leads to better outcomes (angiosome 
concept).  This so called “angiosome concept” was first devised by anatomic 
studies that identified 3D blocks of tissue fed by a single artery44.  The foot has 
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6 angiosomes originating from the 3 below knee arteries and their branches.  
Some studies have shown that revascularisation targeted to the angiosome 
associated directly with the area of tissue lost leads to improved tissue healing 
and limb salvage rates45,46.  However no randomised controlled trial has been 
performed to compare whether direct or indirect revascularisation has an impact 
on healing and limb salvage rates. 
Open surgical techniques for revascularisation comprise of bypass surgery 
(anatomical and extra-anatomical) and endarterectomy.  Endovascular 
interventions include percutaneous transluminal angioplasty (PTA) with balloon 
dilatation, stenting and atherectomy devices.  Open surgical techniques are well 
established, whereas the technology and devices available for endovascular 
interventions are continuing to develop and improve.  Advances in balloon and 
stent technology, such as cutting balloons, and catheter and guidewires, such 
as re-entry devices and guidewires for crossing long occlusions47,means that 
durability and indications for endovascular revascularisation continue to 
improve.  More recently drug eluting technology, for example using the 
antineoplastic agent paclitaxel, have been used in an attempt to reduce re-
stenosis in treated lower limb arteries48–50.  Paclitaxel is an inhibitor or vascular 
smooth muscle proliferation51, and is highly lipophilic promoting rapid tissue 
uptake even with brief exposure of the drug to the vessel wall.  The reduction in 
re-stenosis with drug eluting stents and balloons has resulted in greater primary 
and secondary patency in patients undergoing endovascular revascularisation. 
Surgical revascularisation is usually not indicated in patients with IC, unless 
there is significant deterioration in symptoms during a surveillance period whilst 
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undergoing non-surgical management or there is significant impact on the 
patient‟s quality of life.  Revascularisation for claudicants is usually only 
considered if the arterial anatomy is favourable for intervention with the least 
amount of risk to the patient.  For example it would be extremely unusual for a 
IC patient to undergo a distal bypass, but if their disease was confined to iliac 
region and anatomically suitable then iliac angioplasty, which has been shown 
to have a good technical success rate (96%) and long term patency (5 years 
71%)3, may be considered appropriate.   
Arterial bypass surgery is performed by anastomosing a graft proximal and 
distal to the diseased segment of the artery.  For long-term durability bypass 
grafts should be kept as short as possible and there should be minimal disease 
both proximal and distal to bypassed artery.  Anatomical bypasses tend to have 
greater long term patency than extra-anatomical bypass, for example 
aortobifemoral bypass has a 5 year patency of >90% compared with axillo-bi-
femoral bypass which has a patency of 71%3.   
The conduit for bypass surgery can be either autologous vein or prosthetic, for 
example Dacron or polytetrafluroethylene (PTFE).  Prosthetic bypass grafts are 
typically used when performing long bypasses, for example axillo-femoral 
bypass, bypasses involving the aorto-iliac vessels where long-term patency is 
good, and in cases of infra-inguinal bypasses where a suitable vein conduit is 
not available.  Venous bypass grafts have been shown to have a much better 
long-term patency (74-76% 5 year patency) compared to prosthetic grafts (39-
52%)3. 
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The introduction of hybrid operating theatres with fully equipped radiological 
and surgical equipment, along with principles of surgical revascularisation 
(ensuring good inflow and outflow, keeping bypasses as short as possible 
especially if suitable vein conduit is limited) has allowed combined endovascular 
and surgical techniques to be performed.  This allows attempts of dealing with 
multilevel disease in one sitting and may in the future lead to improved 
outcomes for patients, particularly with CLI. 
 
1.2 Anatomy of the Lower Limb 
At the level of the calf the lower limb consists of 4 muscle compartments (Figure 
1.7).  The anterior compartment is composed mainly of the tibialis anterior 
muscle with the long extensors of the foot.  The main arterial supply to the 
anterior compartment is via the anterior tibial artery.  The lateral compartment 
usually represents the smallest compartment in the calf and consists of the 
peroneus longus and brevis muscle.  Blood supply to this compartment is from 
peroneal artery.  The posterior compartment of the lower leg is divided into a 
large superficial and a deep compartment.  The superficial compartment 
comprises the soleus and gastrocnemius muscles.  Both muscles represent the 
largest muscle mass in the calf and whereas in the other muscle compartments 
it can be difficult to distinguish individual muscles, these two muscles are readily 
identifiable.  The deep posterior compartment  
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Figure 1.7:  Compartments of the lower leg at the level of the calf showing the different 
muscle compartments. 
 
consists of the long flexors of the foot, the tibialis posterior and popliteus 
muscle.  The blood supply to the superficial and deep posterior compartment is 
mainly from the posterior tibial artery although collateral branches from the 
popliteal artery also contribute more proximally.  From the anatomy of the lower 
leg it can be seen that the calf can be divided into 5 distinct muscle groups; the 
anterior muscle compartment, the lateral muscle compartment, the soleus 
muscle, the gastrocnemius muscle and the deep posterior muscle compartment 
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1.3 Perfusion imaging 
At present there are no reliable methods for assessing limb perfusion.  The 
imaging modalities mentioned earlier (duplex, CTA, MRA, IADSA) all allow 
accurate assessment of the larger vasculature but provide no information about 
the microcirculation or perfusion at the tissue level.  ABPI can predict significant 
arterial stenosis or occlusion with a high specificity and sensitivity1, but again 
this is does not provide assessment of tissue perfusion. 
An accurate, non-invasive method of mapping and measuring muscle perfusion 
would aid diagnosis and treatment of CLI and may increase limb salvage rates.  
If the angiosome concept is believed to improve limb salvage rates, then 
accurate assessment of segmental tissue perfusion, would help to delineate 
areas of ischaemia, accurately guide interventions on the limb and provide an 
objective means of measuring improvement52.  
 





Methods for assessment of perfusion in organs such as the heart and brain 
have progressed rapidly, however muscle perfusion measurements in the lower 
limb have proven to be more difficult.  The biggest challenge to skeletal muscle 
perfusion imaging is the low basal perfusion at rest.  Skeletal muscle represents 
the largest tissue mass in the human body and at rest receives around 20% of 
the cardiac output, but this can be increased to up to 80% during exercise.  A 
20-50 fold increase in blood flow has been measured in muscle after 
exercise54,55.  Comparatively, brain and cardiac perfusion are constantly well 
maintained by auto regulation and receive around 10-20% of the cardiac output 
(Figure 1.8).  Measurement shows resting blood flow to be between 1-
2.2ml/min/100g muscle54,56 with no difference seen between normal subjects 
and patients with PAD55.  However during hyperaemia, e.g. from exercise or 
vasodilation, skeletal muscle perfusion can increase dramatically up to 80-
100ml/min/100g muscle57.  When this is compared with resting perfusion of 60-
100ml/min/100g in the heart and brain it is understandable why perfusion 
imaging in the resting lower limb has been difficult to achieve.   
This wide variability in skeletal muscle perfusion makes assessment of this 
problematic and challenging due to the high sensitivity that would be needed to 
measure such low blood flow.  To be able to detect measurable changes in 
muscle perfusion in the lower limb, most modalities require a setup where blood 
flow to the tissues is increased, i.e. hyperaemia.  A number of methods have 
been utilised to achieve this, such as: (i) arterial occlusion, typically with a cuff 
inflated to suprasystolic pressures to induce ischaemia and subsequently 
deflated evoking a reactive hyperaemia; (ii) exercise resulting in a functional 
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hyperaemia, or; (iii) the use of vasodilators to increase blood flow, a 
pharmacological hyperaemia.  The use of hyperaemia results in an increase in 
blood flow to the tissue, particularly muscle and can be used to assess 
perfusion as well as physiological reserve, much in the same way as 
vasodilators and treadmill testing is used in patients to measure cardiac 
perfusion. 
A number of methods have been used in the past to measure lower limb 
perfusion, with newer techniques being developed to allow accurate 
measurement of muscle perfusion. 
1.3.1 Current Methods of Measuring Lower Limb Perfusion 
Venous Occlusion Plethysmography  
Venous Occlusion Plethysmography (VOP) was first described at the beginning 
of the 20th century58 but it was only after the introduction of mercury-in-silastic 
strain gauges in the 1950‟s and 1960‟s that it was regularly used to evaluate 
PAD59,60.  VOP relies on the principle that when cuffing occludes venous 
drainage from a limb, the volume of the limb is dependent on the arterial blood 
which can flow into the limb but is unable to escape.  In the lower limb this is 
achieved by inflating a cuff around the thigh to 50mmHg to occlude venous 
drainage without obstructing arterial inflow.  A strain gauge is applied to the calf 
to measure the change in volume in the limb.  An increase in limb volume 
following cuff inflation is recorded via a strain gauge applied to the calf as 
changes in its electrical resistance.  If the strain gauge length is made equal to 
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the limb circumference then changes in limb circumference are directly 
proportional to change in electrical resistance and this can be calibrated to 
quantify limb blood flow61. Under resting conditions it is estimated that up to 
70% of blood flow in to the limb is directed to skeletal muscle with the remainder 
accounted for by skin circulation58.  The change in limb volume can, therefore, 
be considered to be directly related to arterial perfusion of the limb.  
VOP has only been shown to correlate well with ABPI62,63.  One of the 
limitations of VOP is that it provides a global indication of perfusion of the limb 
without any anatomical information and, therefore, cannot be used to delineate 
segmental muscle perfusion. VOP is influenced by numerous factors, such as 
ambient temperature, arterio-venous shunting, which may lead to erroneous 
readings.  
Laser Doppler  
Laser Doppler Flowmetry (LDF) and Laser Doppler Imaging (LDI) measure the 
speed and concentration of blood cells64 (blood flux, not blood flow, Figure 1.9) 
and therefore cannot be used to compare perfusion in different individuals65.    
LDF requires direct contact and is only effective over a relatively limited area 
(~1mm3).  LDI assesses a larger area of skin from a distance using a scanning 
motion that incorporates the entire lower limb and foot66.  The wavelength of 
laser, speed of scanning and distance between the scanner and the leg affect 
tissue penetrance and must be kept constant to allow meaningful comparison of 
serial measurements65.   
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Figure 1.9:  Laser Doppler imaging of the foot at baseline (a).  Suprasystolic cuffing 
induces an ischaemic phase (b) with a decrease in flux in the foot.  Reactive hyperaemia 
after cuff deflation shows an increase in flux (c) with subsequent return to baseline (d).  
Pictures courtesy of Moor Instruments, Devon, UK  
 
LDF/LDI was first used in the 1980s to assess the severity of ischaemia in PAD, 
but these modalities only identify ischaemic compared with normal limbs and 
cannot quantify the severity of perfusion deficit67. More recent studies show that 
LDF is a good discriminator of skin flap perfusion and can predict the likelihood 
of healing after limb amputation68. LDI is used in preclinical animal models of 
limb ischaemia (e.g. the murine hindlimb ischaemia model) for high throughput 
testing of interventions including angiogenic therapies. The technique allows 
longitudinal acquisition of data, but is limited by motion artefact, ambient 
temperature variations and “perfusion” measurements weighted toward the 
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larger vessels that are shallow and reside on the surface of the limb 
musculature42. 
Transcutaneous oxygen pressure (TcPO2)      
The measurement of TcPO2 is a non-invasive technique that allows longitudinal 
assessment of local oxygen diffusion from the capillary bed through the skin 
epidermis and provides an indication of the amount of oxygen delivered to the 
tissue. TcPO2 measurements can reflect the severity of PAD69, assess ulcer 
healing potential70 and determine the optimal level for limb amputation71.  A 
TcPO2 lower than 20-30mmHg is consistent with CLI3,69,72 and levels below 
40mmHg are associated with poor healing following amputation72. Inhalation of 
100% oxygen would normally result in TcPO2  >100mmHg, but in patients with 
CLI the TcPO2 does not rise above 30mmHg72. Oxygen therapy resulting in 
<10mmHg rise in limb TcPO2 is associated with an over 60% chance of an 
amputation at that level not healing72.  A rise of >40mmHg in TcPO2 after limb 
revascularization is considered significant and increases the chances of tissue 
healing69,72. 
TcPO2 measurements vary in different tissues and under different physiological 
conditions.  Barriers to diffusion such as oedema, increased oxygen 
consumption secondary to inflammation, and vasoconstriction may lead to 
falsely low TcPO2 readings.  Readings are also affected by temperature, with a 
1°C reduction in the thermistor temperature resulting in a 2-3% lower TcPO2 
reading72.  
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Indocyanine Green Fluorescence Angiography (ICGA)   
This technique has been used for many years to image retinal vessels73, and 
more recently in the assessment of microanastomoses in surgical flap 
reconstruction surgery, detection of arteriovenous malformations, and 
measurement of hepatic blood flow74. 
Indocyanine green is a fluorescent dye that is activated by near infrared laser 
light at ~780nm75 . This allows a penetrance of 3mm from the surface of the 
skin to assess the subdermal microcirculation74,76. A semi-quantitative measure 
of perfusion is obtained by measuring pixel fluorescence intensity in different 
areas of the image from the limb. Perfusion measured by ICGA correlates with 
LDI in the hind limb ischaemia model77 and predicts the likelihood of amputation 
healing in man75.  This technique can identify patients with peripheral arterial 
occlusions who have extensive collateralization76. Lack of differences between 
the two groups when ABPI has been used as the discriminator, suggests that 
ICGA may be a more sensitive method for assessing perfusion in the limb than 
ABPI.  
The main limitation of all of these techniques is that they only provide 
information on perfusion in superficial tissues.  Analysis of skin perfusion 
misses the muscle compartments, which determines symptomatic and 
functional limitations in PAD.  Changes in skin perfusion in PAD are only reliably 
detected in the later stages of limb ischaemia whereas disturbances in muscle 
microcirculation is seen much earlier78.  Muscle perfusion in end stage CLI 
patients requiring amputation correlates well with skin perfusion measured by 
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TcPO2 and LDF79.  Reliable measurement of muscle perfusion may therefore 
allow intervention at an earlier stage where a more positive outcome in terms of 
limb salvage is achievable. Cutaneous blood flow is highly variable and, 
therefore, is a poor marker of limb perfusion. Autonomic neural dysfunction, as 
seen in diabetes, and the presence of infection, for example, can significantly 
alter skin perfusion.   
1.3.2 Emerging Techniques for Perfusion Imaging   
Positron Emission Tomography (PET)   
This imaging modality was originally used to measure perfusion and absolute 
blood flow to the brain80 and heart81,82, but has also been used to quantify blood 
flow to the musculature of the leg54,55,83.  Myocardial perfusion, assessed by 
PET, correlates extremely well with measurements made using radiolabeled 
microspheres in animals, a technique that is considered the gold standard in the 
laboratory setting82.   
15Oxygen, in water for injection or mixed with air/CO2 for inhalation, is currently 
used in man for imaging perfusion using PET80,83.  A small number of PET 
studies have assessed blood flow, oxygen consumption and oxygen extraction 
in the lower limb54,55,83 and shown that patients with PAD have decreased blood 
flow and oxygen consumption in the affected limb after exercise compared with 
the contralateral “control” leg83. After stimulation with exercise or intra-arterial 
administration of vasodilators, the increase in blood flow (hyperaemia) is less 
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pronounced in patients with PAD compared with young healthy volunteers55,83,84 
(Figure 1.10). 
 
Figure 1.10:  Positron emission tomography (PET) of the calf using 
15
Oxygen-labelled 
water in healthy volunteers and patients with PAD.  At rest little difference is seen 
between the 2 groups.  Reactive hyperaemia provoked with intra-arterial adenosine 




These studies must, however, be interpreted with caution because they do not 
use age matched controls, nor do they re-measure perfusion after limb 
revascularisation.  PET does not offer the same spatial and temporal resolution 
as MR imaging, but its close correlation with microsphere derived perfusion 
measurements in mouse85 and canine86 models of ischaemia renders it the gold 
standard in perfusion imaging. PET requires a lengthy scan time and exposure 
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to ionising radiation precluding serial investigations. 13Nitrogen-ammonia has 
been used extensively as a PET agent for assessment of cardiac perfusion87 
but not for the measurement of muscle perfusion in the lower limb. 13Nitrogen-
ammonia and 15Oxygen both have relatively short half-lives of 10mins and 
2mins, respectively, which limits their versatility. 15Oxygen is better suited as a 
perfusion probe in the lower limb because it is freely diffusible and not affected 
by metabolism.18Fluorine flurpiridaz tracer is an alternative, versatile 
radioisotope for measuring perfusion because of its longer half-life (110mins) 
and high extraction rate but its utility in the clinical setting is still under 
investigation88.    
Contrast-enhanced ultrasound (CEUS)  
CEUS with microbubble contrast agents (measuring 2.5μm in size) can assess 
muscle perfusion89–91. These contrast agents consist of a shell and a gas core, 
the latter endowing echogenicity to the structure.  The outer shell is broken 
down by the acoustic energy of the ultrasound and eventually metabolized by 
the body. The composition of the shell determines how long the contrast agent 
remains in the circulation.  
Assessment of perfusion in skeletal muscle by CEUS is performed with a linear 
ultrasound transducer probe placed around the calf and a region of interest 
(ROI) selected in which only muscle is seen and bone is excluded.  The probes 
used usually have a depth of 4cm beneath the skin and are held in place by 
hand, keeping the ROI in view89.  Microbubble contrast is administered 
intravenously, either as a bolus injection89 or by slow continuous infusion91 with 
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the assumption that signal intensity is a direct measure of microbubble contrast 
concentration in the ROI.  It is not known which method of administration is 
superior.  
 
Figure 1.11:  Contrast enhanced ultrasound (CEUS) signal intensity time curve 
highlighting difference parameters for the assessment of perfusion.  Parameters 
including time to maximum signal, maximum signal intensity and slope of the curve 
during reactive hyperaemia can be analysed to assess muscle perfusion 
 
Changes in muscle perfusion are provoked to help assess perfusion and flow 
reserve. This can be done using a cuff inflated around the thigh to supra-
systolic pressure to occlude the arterial circulation. The cuff is subsequently 
deflated producing a reactive hyperaemia; alternatively the subject exercises to 
induce functional hyperaemia in the muscle and changes in perfusion. In both 
scenarios, signal intensity can be used to quantify perfusion (Figure 1.11), but 
the stressors to increase muscle blood flow in the lower limbs are more difficult 
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to achieve in CLI patients compared with claudicants. Parameters such as time 
to peak (TTP) contrast, maximal contrast, areas under time-signal intensity 
curves and gradients have been used to assess perfusion89,91.  TTP, maximal 
signal intensity and area under the time-signal intensity curves are lower in 
patients with PAD compared with healthy controls89–91.   
CEUS has been used to assess collateralization, an important compensatory 
mechanism in patients with PAD91. Patients with extensive collateralization 
(assessed by angiography) have a shorter time to peak compared with those 
that collateralize poorly91.  In contrast, no difference in ABPI was detectable 
between patients with good and poor collateralization.  
CEUS shows promise for measuring tissue perfusion because it is cheap, easily 
available and does not use ionising radiation, but it remains to be validated 
against other “gold standard” modalities such as 15Oxygen PET.  To date, 
CEUS has only been used to measure perfusion in the gastrocnemius and 
soleus muscle groups. Its use for other calf muscle compartments is limited by 
the presence of bone.  As with all ultrasound techniques, CEUS is operator 
dependent and can be limited by artefacts created by patient movement.  
Although microbubble contrast agents are safe to use92 and only needed in 
small doses, they are rapidly lost in the circulation.  
Computed Tomography Perfusion Imaging (CT)  
Computed tomography (CT) can accurately assess perfusion in the brain93, 
heart94 and solid organs95, but has traditionally been less useful for evaluating 
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perfusion in the limbs.  CT perfusion imaging of peripheral muscle is difficult 
because of the low baseline blood flow to these tissues compared with other 
structures. The signal to noise ratio during perfusion mapping is also affected by 
beam artefact from bone also, which limits the use of CT perfusion 
measurement in the lower limb.  A recently described CT based method has, 
however, overcome this problem by averaging signal intensity changes over a 
number of voxels to improve the signal to noise ratio96.  This technique has not 
been validated against other perfusion modalities and has only been carried out 
in a small cohort of normal subjects and not in patients with PAD.  
 CT imaging of the calf has recently been used to quantify changes in perfusion 
after revascularisation of the ischaemic limb by measuring blood flow, blood 
volume and mean transit time for contrast to reach the muscle97.  This study 
found a significant increase in blood volume and blood flow to the calf post 
intervention, but not for mean contrast transit time. Individual muscle groups 
were not analysed but changes in perfusion were detected after successful 
revascularisation.  CT based methods allow rapid acquisition of perfusion data 
and avoid the need for complex and expensive equipment.  This method 
exposes the patient to ionising radiation and iodinated contrast agents and 
limits the possibility of measuring changes in perfusion by serial scanning. 
Magnetic Resonance Imaging (MRI)  
This is a promising modality for simultaneously assessing limb perfusion and 
the larger vasculature using conventional MRA.  This non-invasive technique 
does not require ionising radiation, thereby allowing serial assessment of the 
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patient. Sequences that show the greatest promise include arterial spin labelling 
(ASL), blood oxygenation level dependent (BOLD) and first pass dynamic 
contrast enhanced (DCE) MRI.  
(i) Arterial Spin Labelling (ASL) MRI  
This technique, developed to measure perfusion of the brain98, has been used 
in the kidney99, heart100 and more recently, skeletal muscle101–103.  ASL uses 
radiofrequency pulse sequences to place a magnetic “tag” onto the water 
component of blood proximal to the ROI.  A T1-weighted image acquired in the 
ROI, after a delay to allow for inflow of tagged blood, is subtracted from a 
control image with no magnetic tagging.  The difference in T1 signal between 
control and tag image is proportional to blood flow and can be used to construct 
perfusion maps over a designated time period104.  ASL MRI can be considered 
analogous to PET perfusion imaging, but unlike PET, only uses blood as an 
endogenous tracer.   
Different methods of ASL are available for perfusion imaging depending on the 
how the tagging is achieved.  Continuous ASL (CASL) involves continuous 
saturation or tagging of arterial water proximal to the imaging slice105.  This 
allows for a steady state in muscle magnetisation to be reached, which 
maximises signal contrast between the control and tagged images.  CASL is 
hampered by magnetisation transfer effects that overestimate perfusion and 
make multi-slice imaging more complex105. Pulsed ASL (PASL) avoids this 
problem by tagging over a spatial region close to the imaging slice in pulses 
and acquiring the tag image between pulses following a post labelling delay.  
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The magnetisation transfer effect is less of a problem with PASL because less 
radiofrequency (RF) power is needed. There is, however, variable delay 
between tagging and blood reaching the imaging slice, which makes absolute 
quantification of perfusion more difficult105.  Alternative sequences, including 
QUIPPS (I &II) and Q2TIPS, have been developed to tackle this problem. PASL 
is also limited by a lower signal to noise ratio compared with CASL.  A method 
known as pseudo-continuous ASL (pCASL) aims to circumvent this problem by 
using short trains of RF pulses to mimic CASL, improving labelling efficiency 
and achieving a higher signal to noise ratio compared with PASL106 (figure 1.12) 
.
 
Figure 1.12:  Pseudo-continuous arterial spin labelling (pCASL) MRI sequence in the calf 
of a healthy volunteer showing echo planar image (a), perfusion map during cuff 
occlusion (b) and reactive hyperaemia (c).  Minimal perfusion is seen during cuff 
occlusion but reactive hyperaemia demonstrates increased perfusion in all muscle 
groups in the calf (signal intensity in arbitrary units (a.u.) in perfusion maps). 
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Like CEUS and PET, reactive hyperaemia or exercise is required to unmask 
perfusion deficits with ASL. This technique allows absolute quantification 
(ml/g/min) of perfusion in the tissues as well as measurement of parameters 
such as peak hyperaemic flow (PHF) and TTP103 in a ROI over time. Although 
ASL has not been validated for the measurement of perfusion in the limb in 
man, comparison with radiolabelled microsphere measurements in the rat 
hindlimb ischaemia model and in the porcine cardiac model have shown good 
correlation for perfusion100,107. TTP increases with the severity of PAD, and PHF 
decreases103.  Analysis of individual muscle groups in the calf reveals that PHF 
is preserved in the soleus with increasing severity of PAD compared to the 
other muscle groups.  This may be explained by the dual blood supply of the 
soleus, which receives blood from both the peroneal and posterior tibial arteries. 
ASL shows that patients with PAD have lower muscle perfusion after exercise 
compared with age-matched controls108.   
ASL provides an objective, quantifiable measure of muscle perfusion without 
ionising radiation or gadolinium based contrast agents, but has limitations 
including: a low signal-to-noise ratio (because magnetically tagged blood 
represents only 0.5-1% of the full tissue signal104); relatively long scan times 
and patient movement causing image artefacts; calculations required to quantify 
perfusion are complex; vascular artefact from large blood vessels causes 
erroneous measurements; transit time (the time taken for blood to travel from 
the “tagging” region to the region of interest) is an important source of error that 
can be potentiated by disease in the peripheral arteries. Echo planar imaging 
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(EPI) provides faster acquisition, but is associated with magnetic field 
distortions, making quantification of the MRI signal complex. 
(ii) Blood Oxygenation Level Dependent (BOLD) MRI  
BOLD MRI uses the saturation state of haemoglobin as an endogenous 
contrast agent.  It uses is discussed in more detail in chapter 1.4. 
(iii) First Pass Dynamic Contrast Enhanced (DCE) MRI  
This MRI technique measures cardiac perfusion and has been adapted for 
assessing perfusion in skeletal muscle109.  T1 weighted MRI sequences capture 
the transit of intravenously administered paramagnetic contrast agents such as 
gadolinium through tissues, and measure changes in signal intensity in the 
muscle.  Mathematical algorithms for tracer kinetics have been investigated to 
estimate myocardial blood flow, but this has yet to be used in the clinical 
setting110. 
A reduction in DCE MRI signal intensity, which correlated significantly with 
radiolabelled microsphere measurements of perfusion, has been demonstrated 
in the presence of ischaemia in the rat hind-limb model111.  In man, DCE MRI 
measures detectable changes in muscle perfusion following thigh cuff-induced 
arterial occlusion of a healthy limb, compared with the uncuffed contralateral 
limb112,113. A small DCE MRI study, lacking age-matched controls, has 
suggested that patients with PAD may have a lower “perfusion index” than 
healthy individuals114.   
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The most significant limitation associated with DCE MRI is the need for 
exogenous gadolinium based contrast agents with their inherent risk of 
nephrogenic systemic fibrosis (NSF) in patients with chronic kidney disease.  
1.3.3 Kinetic models used in contrast-based techniques 
Kinetic models are needed to quantify perfusion using contrast based imaging 
modalities to differentiate between the tracer in the arterial system and in the 
tissues.  In PET imaging, 15Oxygen is freely diffusible into tissue from the 
intravascular space, which means a simple single compartment model can be 
applied to quantify muscle perfusion115.  For DCE-MRI and ASL the modelling is 
more complex and quantifying perfusion is dependent on deconvolving the 
arterial input function (AIF), calculated from a major artery proximal to the ROI, 
from the tissue concentration. A non-linear relationship between AIF 
concentration and signal intensity can introduce errors. Partial volume, signal 
truncation and magnetisation transfer effects can also lead to inaccuracies. 
Finally, the bolus transit time, which is dependent on factors such as cardiac 





1.4 Magnetic Resonance Imaging 
1.4.1 Basic Principles 
MRI has developed as an important clinical imaging modality ever since Paul 
Lauterbur and Sir Peter Mansfield independently developed this technique.  
Both men were awarded the Nobel Prize in 2003 and are considered the fathers 
of clinical MRI, however the origins can be traced further back for well over a 
century by seminal discoveries made by mathematicians, physicists and 
chemists117.   
MRI is based on the electromagnetic activity of atomic nuclei.  A simple 
overview of MRI is shown in figure 1.13.  Nuclei contain protons and neutrons, 
both of which spin around their axis.  Protons possess a positive charge and the 
movement of an electrical charge results in an electrical current.  The presence 
of an electrical current means there is also a magnetic field present.  Hydrogen 
nuclei possess a single proton and clinical MRI scanners exploit the magnetic 
fields created by spinning hydrogen nuclei (protons) within the body.  The 
hydrogen nucleus is the best for MRI as it is largely abundant in man in the form 




   
Figure 1.13: Simple overview of principles involved in MRI 
 
Protons can therefore be thought of as tiny magnets and when placed in an 
external magnetic field (B0), as happens in a MRI scanner, results in their 
alignment in either the parallel or anti-parallel direction to B0, or z-axis of the 
magnetic field (figure 1.14).  Alignment in the parallel and anti-parallel direction 
results in cancelling out of magnetisation, however as protons aligned in the 
anti-parallel direction requires a higher amount of energy, more protons align in 
the parallel direction resulting in a net magnetic field in the direction of B0. 
Patient is placed in a 
magnet 
A radio wave is 
transmitted to patient 
Radio wave is turned 
off 
Patient emits a signal 
Signal emitted is used 
to construct an image 
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Figure 1.14:  Proton spin occurs in random directions (A), which align either in parallel or 
anti-parallel direction to the magnetic field in the presence of an external magnetic field 
(B0). 
 
Interaction of spinning protons with an external magnetic field also results in the 
protons to wobble or precess.  The frequency at which precession occurs is 
calculated by the Larmor equation, and is important because at this particular 
frequency, it is possible to alter the spin of the protons within the magnetic field.  
As a result of proton precession and alignment, magnetization when placed in 
an external magnetic field can be represented as a vector quantity in the 








Figure 1.15:  Protons within a magnetic field not only align but also display a wobble 
motion known as precession.  Magnetisation can therefore be seen as a vector quantity 
in the longitudinal (z-axis) and transverse (xy-axis). 
 
As precession is occurring in all protons, and occurs randomly there is no net 
magnetisation in the transverse plane.  Therefore, when a patient is placed in 
the external magnetic field in an MRI scanner, the result is a net magnetisation 
in the z-axis.  It should be noted that as this is in the plane of B0 this signal 
cannot be measured directly and that only magnetisation in the transverse 
plane is detectable.  To elicit a measurable MRI signal a radiofrequency (RF) 
pulse is transmitted to the patient.  If the RF pulse has the same frequency as 
the precessing protons (which can be calculated using the Larmor equation) 







a parallel to anti-parallel alignment, which results in a decrease in net 
longitudinal magnetisation in the z-axis, and (2) protons which were precessing 
randomly become synchronised and precess together in phase, resulting in the 
formation of net transverse magnetisation in the xy-axis.  As the transverse 
magnetisation precesses around a receiver coil, it induces a current (in 
accordance with the Faraday‟s law of induction). This current ultimately 
becomes the MR signal.  If the RF pulse results in abolishing longitudinal 
magnetisation completely, and the formation of maximal transverse 
magnetisation we can say that magnetisation has been flipped 900, from the z-
axis to the xy-axis.  This is known as the flip angle (FA) in MRI. 
When the RF pulse is turned off, the changes that occurred when the pulse was 
transmitted are reversed.  Longitudinal magnetization recovers as protons that 
moved to a higher energy level anti-parallel alignment flip back to a lower 
energy parallel alignment.  This results in energy release to the surroundings, 
known as spin-lattice relaxation.  If we were to plot the recovery in longitudinal 
magnetisation after the RF pulse is switched off against time we see a curve as 
seen in Figure 1.16, also known as the T1 curve.  This spin-lattice relaxation 
can be described as a time constant (usually measured in milliseconds), T1, 
based on this curve, which represents 63% recovery in the longitudinal 
magnetisation.  Different tissues will have a different T1 dependent its 
composition and surrounding and therefore can be distinguished on MRI 




Figure 1.16:  T1 curve showing the return of longitudinal magnetisation after the RF 
pulse is switched off.  The T1 time represents the time taken for the signal to reach 67% 
of longitudinal magnetisation prior to the RF pulse.  Different composition of different 
tissues results in different T1 times. 
 
The second effect to occur after the RF pulse is switched off is the decay in net 
transverse magnetisation as the protons, which started to precess in phase, 
lose their synchronization.  This is due to the interaction with neighbouring 
spinning protons resulting in inhomogeneities in the magnetic field.  This is 
known as spin-spin relaxation and, as with T1 relaxation can be described as 
time constant, T2.  If the transverse magnetisation decay is plotted against time 
(T2 curve), T2 represents the time taken for decay in transverse magnetisation 
to fall to 37% of its original value (Figure 1.17).  Transverse magnetization can, 
however, be also dephased due to magnetic field inhomogeneities.  The 
magnetic field is not exactly the same everywhere because of the limitations of 
magnetic construction or interaction with compounds that can distort the local 
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magnetic field, such as paramagnetic effects of de-oxygenated haemoglobin.  
The result of these magnetic field inhomogeneities results in a more rapid 
dephasing of precessing protons. The decay in transverse magnetization due to 
these factors is known as T2* decay and takes into account T2 relaxation in 
addition to the magnetic inhomogeneities.  T2* decay is therefore always 
shorter than T2. 
 
Figure 1.17:  T2 curve showing decay in transverse magnetisation after RF pulse is 
switched off.  T2 time is defined as the time taken for the signal to reach 37% of its 
original. Different tissues will have different T2 due to their composition. 
 
1.4.2 Time to Repeat, Time to Echo 
Manipulating the RF pulse forms the basis of the contrast generated with MRI, 
such as T1 weighted, T2 weighted images or contrast due to proton density.  
The two parameters that important in this process are time to repeat (TR) and 
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the echo time (TE).   TR is the time between the applications of two RF pulses 
and is usually measured in milliseconds. TE (also measured in milliseconds) is 
the time between the application of the RF pulse and the peak of the echo 
detected following this application. 
TR is directly related to T1 and affects T1 weighted images.  When TR is short 
(typically less than 500milliseconds) it is possible to detect contrast between 
tissue due to its different composition, usually due to changes in water and fat 
content.  As the T1 of water and fat are different, the amount of longitundinal 
relaxation that will have occurred will be different before the next RF is 
transmitted, which results in the contrast between the two.  Therefore short TR 
will make the image T1 weighted.  If TR is long (typically greater than 
1500milliseconds), the tissues have time to recover their longitundinal 
magnetisation and as such there is little difference seen in T1 signal.   
TE relates to the decay in transverse magnetisation and as such affects 
contrast on T2 weighted imaging.  After a RF pulse is transmitted, transverse 
magnetisation is generated which will decay over time due to loss in 
synchronisation in precessing protons.  However, if were to send in a RF pulse 
that flips magnetisation by 180o, this will result in refocusing of protons returning 
to be in phase, and therefore an increase in transverse magnetisation.  The 
time taken for this refocusing is TE.  The effect of this 180o pulse is to neutralise 
the magnetic field inhomogeneities to produce a pure T2 effect.  If we do not 
use a 180o refocusing pulse however, the decay in transverse magnetisation is 
much faster, and this is due to these magnetic field inhomogeneities and as a 
result this is the T2* decay (Figure 1.18). 
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Figure 1.18:  T2* relaxation is faster than T2 relaxation due to both T2 effect and 
magnetic field inhomogeneities.  An 180
o
 refocusing pulse can eliminate the 
inhomogeneities to produce a true T2 effect.  
 
1.4.3 MR signal localisation  
The area of the body to be examined can be selected by using a gradient field, 
which is superimposed on the external magnetic field. A gradient coils generate 
these gradient fields.  Protons along this superimposed gradient have a 
different precession frequency compared to protons not exposed to the gradient 
field, and thus a RF pulse of can be generated which only excites protons in the 
area we wish to examine. Information detected is stored within the MR system 
in an area termed „k-space‟. Their location is subsequently calculated with 
mathematical modeling using the inverse Fourier transform.  
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1.4.4 MR Sequences 
Pulse sequences are waveforms created from the gradients and RF pulses 
used to generate a particular MR image. Pulse sequences are therefore the 
„sheet music for the MR system orchestra‟; a diagram of the timing instructions 
sent to the RF generator and gradient.  There are two fundamental types of MR 
sequences are used. These are termed the spin-echo (SE) sequence and the 
second is a gradient-echo (GRE) sequence. Other MR sequences are 
essentially variations of these basic types. SE MRI sequences utilize a 90o flip 
angle and a refocusing 180o RF pulse to produce a T2 weighted image, 
eliminating any T2* effect.  GRE sequences differ from SE in that the flip angle 
is usually less then 90o and by the absence of 180o refocusing RF pulse.  This 
results in faster acquisition time compared to SE sequences as transverse 
relaxation recovers more quickly.  As there is no refocusing 180o pulse the MRI 
signal obtained is due to T2* effect and not T2 decay.   
 
MR sequences can be either two-dimensional (2D), with one section acquired at 
a time, or three dimensional (3D) with a volume of multiple sections obtained 





1.5 Blood Oxygenation Level Dependant (BOLD) MRI 
Blood Oxygenation Level Dependent (BOLD) MRI was first developed in 1990 
as a functional tool for mapping changes in oxygenation level in the blood 
supply to the brain118.  The BOLD effect seen on MRI utilises the saturation 
state of haemoglobin as an endogenous contrast agent. Deoxyhaemoglobin is 
paramagnetic, whereas oxyhaemoglobin is diamagnetic, and it influences the 
water proton in its vicinity.  The paramagnetic effect of deoxyhaemoglobin leads 
to increased inhomogeneity in the external magnetic field which results in a 
decrease in the T2* signal.  A decrease in deoxyhaemoglobin, therefore, can be 
observed as increase in BOLD signal in T2* weighted MRI sequences. 
Utilising the difference in magnetic properties of haemoglobin depending on its 
oxygenation status, and linking this with brain activation leading to an increase 
in blood flow119, allowed BOLD MRI to be used to map areas of brain activation 
and subsequently be used as a functional tool to assess brain function and 
perfusion in a variety of neurological pathologies120.  
The development of BOLD MRI to measure brain perfusion preceded its use for 
the assessment of perfusion in other organs.  It has now been used to 
determine perfusion in the heart121–127 and kidney128–135.  The angiogenic drive 
(and associated hyper-perfusion state) in tumours means that BOLD MRI can 
be utilised in the assessment of different cancers and more recently in the 
tumour response to medical therapies136–138.  
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BOLD MRI has also been assessed as a tool for measuring perfusion in skeletal 
muscle, including quantification of perfusion in the ischaemic limbs of patients 
with PAD.  The appeal of BOLD MRI is that it is an image modality that does not 
require the administration of exogenous gadolinium based contrast agents (as 
with DCE MRI), with its inherent risks of NSF in patients with chronic renal 
impairment, and does not expose patients to ionising radiation (as with PET or 
CT). 
BOLD MRI was first used for measuring limb perfusion by Toussaint et al in 
1996139, who demonstrated a good correlation between perfusion measured by 
BOLD MRI and VOP in normal subjects.  This stimulated more studies in 
utilising BOLD MRI to measure perfusion in skeletal muscle.   
BOLD MRI measurements are usually taken through a section of the calf at 
rest.  As mentioned before, hyperaemic response is required to evoke a 
measurable change in perfusion.  Reactive hyperaemia after arterial occlusion 
offers the most reliable method of achieving this, and has been used in almost 
all BOLD MRI studies.  T2* signal changes are measured prior to cuffing, during 
arterial occlusion inducing transient ischaemia (usually for a few minutes) and 
after cuff deflation provoking reactive hyperaemia.  Signal intensity time course 
curves are generated from changes in T2*.  Different parameters from this 
curve have been used to assess perfusion and, probably more importantly, 
changes in perfusion associated with the increased demand of reactive 
hyperaemia.  Curve parameters most commonly used to assess muscle 
perfusion include minimum T2* during ischaemia (T2*Min), TTP, time to half 
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ischaemia (THIM) and maximum T2* (T2*Max) during reactive 
hyperaemia140,141. 
BOLD MRI has been used to detect changes in muscle perfusion in patients 
with PAD and healthy controls101,142–144. Patients with PAD have significantly 
reduced T2*Max and a prolonged TTP compared with age-matched healthy 
controls142. 
In patients with PAD undergoing revascularisation with angioplasty it has been 
shown the T2* signal intensity returns to baseline faster and there is a trend 
towards a higher T2*Max value and faster TTP, when compared with pre 
angioplasty of superficial femoral artery lesions in patients with intermittent 
claudication143, indicating that arterial revascularisation has an impact on the 
BOLD MRI signal. 
Changes in BOLD T2* signal intensity correlate with: LDF and TcO2 (measure 
skin perfusion) in the ischaemic-reactive hyperaemic model144;  tissue 
oxygenation (measured by myoglobin proton MR spectroscopy)145; and  
perfusion measurements made using VOP adapted for MRI and ASL MRI139.   
Age related in muscle perfusion has also been investigated146,147.  Studies have 
demonstrated that older subjects have a lower T2*Max, longer TTP and longer 
THIM compared to younger controls.  Age related changes in muscle perfusion 
are due to a combination of reduced capillary density, increased vascular 
rigidity, increased sympathetic vasoconstriction and/or reduced 
vasodilatation148–152.  If BOLD MRI is able to detect age related changes in 
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muscle perfusion without overt signs of PAD, then it can be reasoned that it can 
used to assess conditions where perfusion may be altered due to factors other 
than PAD, such as chronic compartment syndrome153 and systemic sclerosis154.   
Although the source of the BOLD signal in peripheral skeletal muscle is not fully 
understood, it is generally accepted that the signal is mainly related to tissue 
oxygenation state140,141.  BOLD MRI, unlike ASL, DCE MRI and PET, does not 
allow absolute quantification of perfusion, but instead relies on ratios in signal 
changes for semi-quantitative measurements.  BOLD does, however, produce a 
better signal to noise ratio, which allows superior spatial and temporal resolution 
compared with ASL MRI.  The lack of reproducibility has also been a weakness 
of BOLD MRI in the assessment of muscle perfusion155. 
 
1.5 Rationale for this study 
CLI is major cause of morbidity and mortality5.  Revascularisation is the 
mainstay of managing these patients to relieve their symptoms and prevent 
major limb loss in the future.  Nevertheless up to a 30% of patients will 
eventually require a major amputation1,3.  Traditionally revascularisation of the 
limb has concentrated on improving the major arteries leading to the limb, either 
with angioplasty or with open surgical techniques.  This improves the “inflow” 
into the limb with the aim of increasing perfusion to the muscle.  The 
pathophysiology of PAD is for one reason or another a lack or blood supply to 
the muscle in the limb, which may involve the major arteries supplying the limb, 
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but may also include a component of microvascular disease restricting 
perfusion at the more cellular level, as is the case in patients with diabetes 
mellitus.   
At present we have no reliable method for the assessment of muscle perfusion 
in the leg52.  Current methods to assess perfusion, such as VOP, LDI and 
TcPO2 either measure global changes in the limb or skin perfusion and can be 
unreliable.  At present the success of revascularisation in patients with PAD is 
ultimately assessed by clinical improvement in symptoms.  In the case of CLI 
and tissue loss, the clinical improvement is not immediate and therefore these 
patients have to wait to see if improvement occurs over a number of weeks.  In 
a number of these patients a window of opportunity may be lost to intervene 
early to improve perfusion further if the revascularisation performed is ultimately 
found to be inadequate to rescue the limb.  An imaging modality that assesses 
perfusion in the muscle directly and that can assess perfusion in individual 
muscle compartments may help in the management of patients with PAD, and 
reliably assess the success of revascularisation, with the ultimate aim to trying 
to improve limb salvage.    
New developments on the horizon including stem cell and angiogenic cell 
therapies may help to improve the perfusion at the cellular level via 
angiogenesis and arteriogenesis39,41,42.  Having a reliable, reproducible method 
to assess muscle perfusion may aid in the development of these techniques by 
identifying targets for cell therapy and to monitor changes in perfusion to 
identify if the treatment is successful.   
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More recently the concept of angiosomes44 has been introduced in the planning 
of arterial revascularisation45,46.  If the angiosome concept is to be believed then 
targeted revascularisation of arteries supplying the area to the lower limb mostly 
affected by PAD may improve the outcomes, particularly in CLI.  Following this, 
an imaging modality they can assess segmental muscle perfusion would allow 
for identification of regions of the lower limb that are most ischaemic to target 
intervention and monitoring the success of revascularisation.  Methods such as 
VOP and ABPI assess global change in the limb and as such would not identify 
particular angiosomes that require intervention. 
An ideal imaging modality for the assessment of muscle/tissue perfusion in the 
lower limb would need to provide reliable and reproducible quantative or at least 
semi-quantative measures of perfusion with minimal risk to patients.  MRI is 
attractive in that it does not subject the patient to exposure to ionising radiation, 
as with CT or PET.  Also more recent developments in MRI sequences (ASL 
and BOLD) allow for the use of endogenous contrast agents without the need 
for intravenous administration of contrast (as with CEUS, CTA, DCE MRI, 
IGCA).  MRI also provides anatomical information allowing for segmental 
assessment of muscle perfusion (unlike VOP and ABPI) and assesses deeper 
tissue perfusion, not just skin perfusion (unlike LDI, TcPO2).   
Therefore both BOLD and ASL MRI represent very attractive methods for 
assessing muscle perfusion.  ASL has the advantage of providing absolute 
quantitative measures of muscle perfusion but requires complex kinetic 
modelling, which has the ability to introduce errors in the measurement.  
Although BOLD MRI does not provide absolute quantitative measure of 
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perfusion it does have a much better signal to noise ratio compared to ASL, 
which helps in obtaining reliable and potentially reproducible measures of 
perfusion.  As most perfusion imaging modalities require a model of evoking a 
hyperaemic response of some kind, and actually the changes in perfusion seem 
to provide more useful information rather than absolute measures of muscle 
perfusion, the disadvantage of not having absolute measures with BOLD MRI 
seems to be diminished.  Also the advantage of using MRI perfusion imaging 
means that it can be easily combined with conventional MRA to provide both 
functional and anatomical imaging in patients with PAD, which can assist in 
planning and surveillance after intervention.  The improved spatial resolution of 
BOLD MRI compared to ASL also makes this more attractive as imaging 
technique.   
The introduction of advanced MRI perfusion techniques to assess tissue 
perfusion in other regions of the body along with the lack of a true measure of 
muscle perfusion in the lower limb warrants investigation to see if techniques 







BOLD MRI can be used reliably and in a reproducible manner for the objective 
assessment of muscle perfusion in the lower limb. 
1.7 Aims 
1. Develop MRI sequences to accurately measure signal changes in 
BOLD contrast. 
2. To assess the reproducibility of BOLD MRI for measuring muscle 
perfusion in the lower limb. 
3. To quantify calf muscle perfusion, using BOLD MRI, in patients with 
CLI and compare this with normal healthy and age-matched controls. 
4. To correlate changes in perfusion measured with BOLD MRI using 
histological measures of vascularity.  
5. To evaluate the utility of BOLD MRI in the assessment of changes in 








General Methods for Imaging & Image Analysis 
2.1 Introduction 
Methods for imaging subjects with MRI and the analysis of images were 
consistent throughout the study and will be explained in this chapter.  
2.2 Study Participants 
This study complies with the Declaration of Helsinki and ethical approval for the 
recruitment of subjects to the study was obtained from the local ethics 
committee at Guy‟s & St Thomas‟ NHS Foundation Trust (10/H0804/67)(See 
Appendix 1).  Subjects recruited for this study included young healthy controls 
without PAD, patients with critical limb ischaemia who were under the care of 
the Department of Vascular Surgery at Guy‟s & St Thomas‟ Hospital, and age-
matched controls recruited from friends and family of patients, non-vascular 
patients admitted to hospital (e.g. hernia patients) and hospital volunteers. Age 
matched controls did not have evidence of PAD determined by ABPI and 
palpable pedal pulses.  All subjects were provided with written information 
regarding the study and written consent was obtained. 
All subjects recruited to the study were screened to assess eligibility to undergo 
scanning with MRI.  To conform to local guidelines all subjects were required to 
complete a questionnaire, which was authorised by a trained MRI user, prior to 
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admission into the scanner. Exclusion criteria were: (i) presence of cardiac 
pacemaker/defibrillator or other magnetically active implants, such as cochlear 
implants, neurostimulators or insulin pumps; (ii) severe claustrophobia; (iii) fixed 
flexion deformities of the lower limb where the subject is unable to place the leg 
flat on the MRI table; and (iv) subjects unable to consent. 
2.3 MRI 
All subjects were scanned at 3 Tesla with a Philips Achieve scanner (Philips 
Healthcare, Best, The Netherlands).  A 32-channel RF cardiac coil was placed 
over the lower calf of both limbs.  The RF coil was fixed to the imaging table 
with the aid of Velcro straps to prevent coil movement.  Both legs were fixed 
with the aid of sandbags to minimise movement artefact during scanning 
(Figure 2.1).  All subjects were scanned on the same scanner.  In all subjects a  
 
Figure 2.1:  Setup of subjects in the MRI scanner, with thigh cuff in place and 32-channel 
RF coil placed on the lower leg, centred on the largest part of the calf. 
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T2 weighted image was also acquired at the same level of the calf as for 
perfusion imaging to accurately highlight the anatomy of the calf. MRI scanning 
time for all the perfusion-imaging sequences, along with anatomical scans was 
in the region of 20-25minutes.    
All subjects were asked to refrain from nicotine, caffeine and strenuous exercise 
4hours prior to imaging.  The reason for this was that caffeine and nicotine are 
vasodilators, which may influence the ischaemia and reactive hyperaemia 
provoked with suprasystolic thigh cuffing.  Similarly, strenuous exercise results 
in changes to perfusion in the lower limb with subsequent changes in T2* 
signal.  All subjects were required to rest supine for a minimum of 5minutes 
prior to the start of the scan to reduce venous filling in the limb, which has been 
shown to influence T2* signal101. 
2.4 Cuffing Model for Eliciting Ischaemia & Reactive 
Hyperaemia 
To elicit measurable changes in T2* a cuffing model was chosen to evoke first 
ischaemia and then subsequent reactive hyperaemia.  This model was chosen 
over others for a number of reasons.  The use of thigh cuff inflated to 
suprasystolic pressure and subsequently deflated allows for complete occlusion 
of inflow and outflow from the leg.  This minimises the influence of venous filling 
on the T2* signal.  This model also allows for standardisation for all participants 
in the study, as everyone is subjected to the same stress.  Cuffing also 
eliminates the need for subject compliance during the study, therefore further 
reducing error.  Finally the use of a cuff, as opposed to exercise models for 
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reactive hyperaemia, reduces motion artefact which would degrade image 
quality and affect image analysis of T2* signal. 
Both legs were imaged with MRI and therefore both legs were cuffed, except for 
when assessing different MRI sequence.  During development one leg was 
cuffed at a time to allow comparison of different MRI sequences sensitive to 
T2*.   A 20cm MRI compatible cuff placed around the thigh was used.  The 
dynamic imaging protocol was as follows: 2minutes baseline measurement, 
prior to cuff inflation to suprasystolic pressures.  The cuff was then rapidly 
inflated, within 20seconds to 50mmHg above systolic pressure and maintained 
at this pressure for 5minutes (Ischaemic Phase).  After 5minutes of the 
ischaemic phase the cuff was rapidly deflated via a one-way valve to evoke 
reactive hyperaemia.  Scanning continued after cuff deflation for 5minutes.  
Therefore dynamic functional imaging took 12minutes (Figure 2.2).  The same 
investigator was used to inflate the cuff each time.
 
Figure 2.2:  Protocol for thigh cuff inflation and deflation to induce ischaemia and evoke 









2.5 T2* response 
Using the cuffing model to elicit ischaemia and reactive hyperaemia results in 
typical changes in T2* signal.  During baseline imaging at the start of dynamic 
imaging the T2* signal is constant.  Initiation of cuff inflation to suprasystolic 
pressures results in occlusion in flow to the muscle.  This results in a decrease 
in oxygenated haemoglobin and with utilisation of oxygen an increase in 
deoxygenated haemoglobin.  This results in a decrease in T2* signal during 
cuffing.  When the cuff is deflated perfusion is increased.  This results in an 
influx of oxygenated haemoglobin and washout of deoxygenated haemoglobin.  
The T2* signal rapidly increases to reflect this and results in an overshoot 
above the baseline as more oxygenated haemoglobin is delivered then is 
required.  The overshoot settles back to baseline, as equilibrium between 
oxygenated and deoxygenated haemoglobin is re-established (See figure 2.3).  
2.6 Image Analysis 
To assess changes in perfusion using BOLD MRI signal intensity time course 
curves need to be generated throughout the dynamic imaging phases.  Different 
regions of interest (ROI) can be drawn in individual muscle compartments or 
groups to identify segmental changes in T2* in the lower leg.     These curves 
show the change in T2* signal as a result of cuffing and decuffing.  Different 





Figure 2.3:  Typical T2* signal response in a normal subject.  Steady signal at baseline is 
followed by a decrease in T2* signal with cuff inflation and ischaemia.  Cuff deflation 
results in reactive hyperaemia represented by an increase in T2* signal and overshoot 
before the signal falls back to a steady baseline. 
 
Dicom files of T2* images acquired, either T2* weighted EPI images or T2* 
maps from the GRE sequence, were imported into the software for analysis.  
For this study we used 5 muscle groups in the calf (anterior, lateral, soleus, 
gastrocnemius and deep posterior) to draw our ROI‟s in each leg.  The T2 
weighted anatomical image allowed for accurate delineation of each individual 
muscle compartment (Figure 2.4). This allowed comparisons of different muscle 
compartments, with their inherent blood supply.  The use of the muscle 

















compartments also allows easier exclusion of major blood vessels, bone and 
soft tissue from the analysis allowing accurate delineation of T2* signal changes 




Figure 2.4:  T2 weighted anatomical image demonstrates the muscle compartment in the 
calf (A=Anterior, L=Lateral, D=Deep, S=Soleus, G=Gastrocneumius)  
 
 
To improve reliability and reproducibility of BOLD-MRI software was developed 
for automated analysis of images using MATLAB (Mathworks, Mass, USA) 
routines (Appendix 2).  The software allowed the user to: 
1. Import DICOM images from the dynamic imaging in a time ordered 
fashion for analysis of T2* signal changes. 
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2. The user to manually input ROI‟s in individual muscle groups on 
functional images, using the T2 weighted anatomical images. 
3. The user to manually adjust the ROI‟s to account for any motion or 
volume changes in the limb related to cuffing and decuffing. 
4. Automatic generation of signal intensity time course curves for each 
ROI inputted on a pixel by pixel basis for each region. 
5. Automated analysis of different curve parameters. 
Different aspects of the signal intensity curve can be analysed as a marker for 
perfusion.  We analysed all parts of the curve using the automated software to 
try to identify the most informative parameter using the ischaemia-reactive 
hyperaemia cuffing model.  Traditional measures from the curve have included 
TTP, T2*Max, T2*Min and THIM.  However there are more aspects to the curve 
that can be assessed and some of the more traditional parameters can be 
assessed with a more accurate and objective method.  The various parameters 
measured are shown in figure 2.5. 
The software automatically generated signal intensity time course curves for 
each ROI inputted.  From the curves the software calculated various 
parameters as follows.  The gradient (Grad) was calculated by taking the first 
derivative of each point after cuff deflation until the maximum T2* value, and 
then taking the mean for the highest 10 values during this period.  Signal 
reduction during the ischaemic phase (SRi) was calculated as a percentage 
drop in T2* signal from mean during initial baseline to the minimum T2* at the 
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Figure 2.5:  Typical T2* signal intensity time course curve showing all the parameters 
assessed with the analysis software program 
 
end of the ischaemic phase.  Baseline at the start was calculated as a mean of 
T2* signal over 90 seconds prior to cuffing, excluding 15seconds at the start of 
the scan and 15seconds before cuff was inflated.  Baseline at the end was 
measured as a mean of the last 90seconds of dynamic imaging with BOLD-
MRI.  T2*Min value was calculated as the lowest T2* signal intensity prior to 
reactive hyperaemia and similarly T2*Max value was calculated as the highest 
signal after cuff deflation and initiation of reactive hyperaemia.  TTP was 
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measured as time from cuff deflation till the maximum T2* in reactive 
hyperaemia.  The time to half ischaemia (THIM) was calculated as the time from 
the start of the scan until 50% reduction in T2* signal after cuff inflation. 
Image analysis was carried out by myself for all scans, with a second blinded 
user for reproducibility studies.  The process of image analysis as described 
above took in the region of 20-30minutes with generation of signal intensity time 
course curves and curve parameters.  Normalised signal intensity time course 




During this study, a standardised method for imaging subjects was used.  This 
allowed for reliable and objective assessment between subjects.  All subjects 
were imaged using the same 32-channel RF coil, with the same investigator 
used to inflate the cuff.  The same MRI scanner was used.   Also as both legs 
were imaged during BOLD-MRI development it was possible to use individual 
limbs, cuffed sequentially to compare different sequences.  When comparison 
was made between patients and controls it was possible to use both legs in 
control patients to gather perfusion data, and also in PAD patients the 
symptomatic limb as well as the contralateral limb could be analysed. 
The ischaemic-reactive hyperaemia cuffing model was utilised as this provides 
the most reliable and reproducible model for evoking changes in muscle 
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perfusion in the limb140,141.  This model eliminates any motion artefact, which is 
particularly problematic in cross-sectional imaging, such as with BOLD-MRI.  It 
also allows for a standardised method to provoke the stress.   
Other methods to evoke reactive hyperaemia include the use of vasodilators, 
exercise and inhaling oxygen.  The use of vasodilators, such as adenosine or 
prostaglandins, to evoke reactive hyperaemia requires invasive cannulation and 
extra monitoring of subjects is needed.   Although vasodilators are generally 
thought to be safe, there are side effects associated such as chest pain, light 
headedness and difficulty breathing and are contra-indicated in certain cases.  
Further, they usually required to be administered via an intra-arterial route to 
provide maximal vasodilation, which carries a higher risk of complications, such 
as infection, bleeding and vessel injury, compared to intra-venous access.   
Exercise testing has been extensively utilised as a method for producing 
reactive hyperaemia.  The use of pedal ergometers allows for standardisation of 
the amount of work required by subjects.  The problems arise with motion 
artefact, as perfusion assessment is required fairly rapidly after the cessation of 
exercise.  It is not possible to perform MRI assessment during exercise as 
motion significantly degrades image quality and makes analysis of during a 
dynamic sequence almost impossible.  Also for MRI, a compatible ergometer is 
required that can safely be used within the magnetic field of an MRI scanner.  
Exercise stressing also requires compliance on behalf of the subjects.  This can 
more problematic in patients with PAD, where they are not able to achieve the 
amount of work required before the onset of symptoms of pain. PAD patients 
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also find it harder to keep their limbs still after exercise increasing issues with 
motion artefact. 
Oxygen inhalation has also been used to increase the BOLD signal156–158.  
Problems with this method arise as most healthy individuals have an oxygen 
saturation of 98-99% and so inhalation of supplemental oxygen does not result 
in an increase in oxygenated haemoglobin but instead an increase in dissolved 
oxygen in the blood.  This does not result in a major change in the ratio 
between oxygenated and deoxygenated haemoglobin, which forms the basis of 
the signal in BOLD-MRI.  Also this method relies on adequate oxygen transfer 
in the lungs, which maybe impaired in patients with respiratory disease, making 
it difficult to distinguish between a ventilation deficit and oxygen delivery 
capacity. 
The low perfusion of muscle at rest, coupled with the variability seen during 
exercise makes assessment of muscle perfusion difficult.  This means the use 
of these models is important in measuring muscle perfusion because they 
ensure changes of perfusion throughout the duration of functional imaging and 
it is these changes that provide measurable outcomes when using many of the 
modalities.  To be able to analyse these changes forms the basis by which 
BOLD-MRI is used as a tool for assessing muscle perfusion.  The expected 
change in T2* signal provides a template by which we can determine perfusion 
changes in pathological conditions.  Therefore it is important to have a robust 
method to analyse the functional images.  The image analysis program 
developed here allows for a semi-automated method to determine changes in 
BOLD signal as a marker of perfusion, where the input of regions of interest is 
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required by the user, but the generation of signal intensity time course curves 
and the analysis of different curve parameters is done in an automated fashion.  
This allows for a standardisation of the analysis with a view of improving the 
reliability and reproducibility of BOLD-MRI.  Previous studies have highlighted 
this as an issue when using this modality155. 
Previous studies with BOLD-MRI have identified certain curve parameters most 
useful in distinguishing between patients and controls101,139,142–144,147,153–
166101,139,142–144,147,154,155,157,159–166.  TTP, T2*Max, T2*Min and THIM have been 
shown to be most informative.  However, analysis of these parameters can be 
difficult, particularly in patients with PAD.  For example, when measuring TTP 
the overshoot in reactive hyperaemia can be difficult to identify.  Also absolute 
measures of T2*Max and T2*Min can make comparison between subjects 
troublesome as the absolute values can differ from patient to patient.  For 
circumvent some of these issues new parameters from the time course curves 
were identified.  Grad measures the slope of the reactive hyperaemia portion of 
the curve and is analogous to TTP, but as it is not dependent on an identifiable 
peak value overcomes this shortcoming.  SRi interrogates the ischaemic part of 
the curve and represents a percentage fall in signal during ischaemia.  This 
overcomes the issues of using absolute values in measuring T2*Min, allowing 
for meaningful comparisons of values between subjects. 
All imaging for this study was carried out using a 3T MRI scanner.  Imaging at 
this higher magnetic field, compared to more conventional 1.5T scanners 
improves the signal to noise ratio when utilised in BOLD-MRI127,160,167.  Imaging 
with a higher magnetic field scanner will also increase the sensitivity to 
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magnetic field inhomogeneities, with improved sensitivity to BOLD signal.  The 
signal generated in BOLD-MRI is miniscule, approximately a few percent at 
1.5T, making it difficult to distinguish above the intrinsic noise167.  3T scanners 
are now becoming more available in clinical use and there is now research 
being performed in humans on 4.7T, 7.0T and even 9.4T scanners.  With the 
advances in both magnetic field strength and with computing power to develop 















Development of BOLD MRI Sequence 
3.1 Introduction 
BOLD-MRI has traditionally been performed using echo-planar imaging (EPI) 
MRI sequences.  EPI are fast acquisition MRI sequences that allow for speedy 
acquisition of k-space.  However, the speed of acquisition comes at the cost of 
spatial resolution.  Nevertheless, the speed of EPI makes it very attractive in 
BOLD-MRI, as temporal resolution is important in detecting changes in signal 
over time in response to stressors, such as in the ischaemia-reactive 
hyperaemia model.  EPI sequence can come a variety of guises depending on 
the weighting of images needed.  For BOLD-MRI the sequences need to be T2* 
weighted to capture BOLD signal in the tissue.  This can be achieved with EPI 
using a gradient echo method (GE-EPI).  As already discussed, to make 
sequences sensitive to T2* the 180o refocusing pulse used in SE-MRI is absent 
and that is the case in GE-EPI.  Signal acquisition is achieved by using gradient 
echo trains to acquire complete or partial k-space.  This use of gradient trains 
with a single RF pulse allows for the rapid acquisition.  Therefore it can be 
surmised that EPI gives excellent temporal resolution, at the expense of spatial 
resolution. 
T2* weighted images can also be acquired using gradient echo (GRE) 
sequences.  Similar to EPI, GRE does not have an 180o refocusing pulse to 
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make it sensitive to T2*.  It does not afford the same fast acquisition time as EPI 
due to the longer time needed to fill of k-space.  The advantage of GRE over 
EPI is the spatial resolution is much improved as is the signal to noise ratio.  
With improvements in MRI processing power the temporal resolution has been 
improved, and also the signal to noise ratio can be further enhanced by the use 
of more echoes.  These improvements, coupled with an increase in field 
strength of scanners results in closing the gap between EPI and GRE when 
utilised for BOLD-MRI.  Almost all the studies using BOLD-MRI to assess 
perfusion in skeletal muscle have utilised GE-EPI sequences101,139,142–144,147,153–
166.   
One of the criticisms levelled against BOLD-MRI is that it does not provide any 
values of absolute quantification of perfusion, unlike ASL-MRI.  The differences 
between ASL and BOLD-MRI have been discussed before (See chapter 1.3.1 & 
1.5).  The main disadvantages of ASL are the lower signal to noise ratio and 
spatial resolution compared to BOLD-MRI.  Also the kinetic modelling required 
to analyse the signal changes can introduce errors.  The argument of absolute 
quantification of perfusion can be countered in the assessment of perfusion in 
the lower limb by the low perfusion of muscle at rest, and therefore the need for 
induction of hyperaemia to measure perfusion.  Studies using ASL-MRI in the 
lower limb have relied on measuring parameters of the signal intensity time 
course curves during changes in perfusion rather then report absolute perfusion 
measures, much like BOLD-MRI does. 
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The sequences used in the assessment of perfusion in the lower limb were 
investigated in the present study, with the aim of trying to identify the most 
reliable method to use in future studies. 
3.2 Aims 
(i) To develop a gradient echo (GRE) MRI sequence that is sensitive to BOLD 
contrast, with improved spatial resolution over standard gradient echo, echo 
planar imaging (EPI) MRI and which can also accurately quantify T2* signal. 
(ii) Compare GRE MRI with EPI MRI in the assessment of BOLD signal. 
(iii) Compare the spatial resolution of GRE BOLD-MRI with ASL techniques for 
assessing muscle perfusion 
3.3  Methods 
3.3.1 Study Participants 
Prior to testing the different MRI sequences on humans, water-based MRI 
phantoms were used to test scanning parameters and MRI performance 
throughout the dynamic sequence before testing on human subjects.  These 
phantoms were used to ensure the scanner hardware was able to process the 
sequences throughout the dynamic imaging phase.  The increase in the number 
of echoes used results in an increase demand on the processing ability of 
scanner hardware and scanning with the MRI phantoms allowed for 
assessment of this processing capability of the BOLD-MRI sequence. 
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Young healthy volunteers with no evidence of PAD were recruited to compare 
the different MRI sequences.  All subjects provided written consent to 
participate in the study.  All subjects were prepared for scanning as described in 
chapter 2.3.  For comparing the EPI and GRE BOLD-MRI sequences each leg 
was cuffed separately and sequentially, with one limb used to test the EPI 
sequence and then the cuff placed on the contralateral limb to test the GRE 
sequence.  The setup for cuff inflation and deflation is described in chapter 2.4.  
For ASL-MRI both limbs were cuffed at the same time. 
3.3.2  MRI Sequences 
All MRI scans were performed on a 3 Tesla Philips Achieva scanner, with a 32-
channel cardiac RF coil.  Two sequences were developed to study changes in 
T2* signal intensity.   
GRE MRI Sequence 
The first was a multi-echo single shot gradient echo (GRE) sequence.  A 10mm 
slice at the widest part of the calf was acquired, with a field of view (FOV) 
including both legs of 288 x 288, and voxel size of 1.1 x 1.1 x 10mm3.  
Parameters for imaging were as follows; time to repeat (TR) 66ms, 14 echo‟s 
with time to echo (TE) 4.6ms, 9.2ms, 13.8ms, 18.4ms, 23.0ms, 27.6ms, 
32.2ms, 36.8ms, 41.4ms, 46.0ms, 50.6ms, 55.2ms, 59.8ms, 64.4ms, Flip angle 
20°.  Image acquisition for the 14 echoes was every 3seconds.  This sequence 
allows accurate quantification of T2*.  T2* maps were then reconstructed from 
the GRE BOLD-MRI sequence online by a Maximum Likelihood Estimate fit with 
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Rician noise correction, where noise is read in k-space, for precise and 
unbiased automated estimation of T2*.  Dicom images of the T2* maps were 
exported to the image analysis software program. 
EPI MRI Sequence 
The second sequence was a multi shot gradient echo echo-planer imaging 
(EPI) sequence weighted to T2* signal changes.  Image acquisition was every 3 
seconds taking ten 5mm slices, 5mm apart around the widest part of the calf.  
Due to the faster image acquisition that is possible with EPI more slices were 
able to be imaged at the same time compared to the single slice acquired with 
GRE BOLD-MRI.  Image parameters were TR 3000ms, TE 35ms with echo 
train length (ETL) of 39.  This sequence allows imaging at different levels of the 
calf and measured changes in T2* signal but does not allow us to quantify T2*.  
Dicom images of the EPI T2* signal changes were exported to the image 
analysis software. 
ASL MRI Sequence 
ASL-MRI was performed on the same scanner with same 32-channel RF coil.  
A pCASL sequence, using a single shot, gradient echo EPI sequence was 
chosen as this gives good spatial resolution.  Both limbs were cuffed 
simultaneously, with baseline imaging of 2minutes prior to cuffing, 5minutes 
image acquisition with the cuff inflated to suprasystolic pressures and 5minutes 
imaging after cuff deflation.   10mm slice thickness was acquired at the widest 
part of the calf.  Image acquisition was every 4 seconds with a FOV involving 
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both legs of 288 x 288.  Imaging parameters were; TR 3600ms, TE 17ms, flip 
angle 90o, with a tagging duration of 2seconds and post labelling delay of 
1900ms. 
3.3.3 Image Analysis 
Signal intensity time course curves were generated for both the EPI and GRE 
BOLD-MRI sequences from different limbs in each subject and compared.  The 
EPI sequence was sensitive to T2* but did not quantify the signal, therefore was 
represented in arbitrary units and measured changes in T2* signal.  The GRE 
sequence was able to quantify T2* signal and as there was a discrepancy 
between units of the signal comparison of curve parameters was not conducted.   
Changes in signal intensity were measured with pCASL to generate perfusion 
maps and also spatial resolution was looked at.  Complex kinetic modelling was 
not carried out to absolutely quantify perfusion, as this was a comparison study 
only.    
3.4 Results 
3.4.1 MRI Sequence Testing on a MRI Phantom 
MRI sequence testing was carried out using a water-based phantom for both 
the EPI and GRE BOLD-MRI.  The purpose of the sequence testing was to 
ensure that imaging parameters were compatible with the scanner, and to test 
the performance of the individual sequences.  Scanning was performed for 
12minutes to simulate the dynamic portion of imaging, i.e. when cuff inflation 
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and deflation would occur.  Similarly, the pCASL sequence was tested on the 
same phantom. 
All 3 sequences were compatible with the processing capabilities of the 
scanner.  No problems related to sequence parameters leading to the scanner 
being unable to acquire and process the images were encountered.  These 
studies in the phantom were important to confirm that despite the high 
processing power needed to acquire and process the 14 echoes of GRE BOLD-
MRI, this sequence was compatible with both the hardware and software of the 
scanner. 
3.4.2 Comparison of EPI versus GRE BOLD-MRI 
The 2 BOLD-MRI sequences were tested on 2 healthy volunteers, both male, 
median age 24years.  The left leg was cuffed first and imaging acquired using 
the GRE BOLD-MRI sequences.  The cuff was then placed on the right leg and 
imaging performed with the EPI BOLD-MRI sequence. 
The higher spatial resolution of the GRE sequence over EPI BOLD-MRI is 
shown in figure 3.1, which is from the same subject.  
Signal intensity time course curves were generated from ROI‟s drawn in the 
anterior, lateral, gastrocnemius and soleus muscle groups for each subject and 
for each BOLD-MRI sequence.  The curves were then compared with each 
other to identify changes in T2* signal with cuff inflation and deflation, and to 




Figure 3.1:  EPI (a) versus GRE (b) BOLD-MRI showing the higher spatial resolution 
achieved with GRE sequence showing axial image from the calf.  
 
The signal intensity curves both subjects using the different BOLD-MRI 
sequences for the 4 muscle groups are shown in figure 3.2.  The EPI sequence 
is sensitive to changes in T2* but does not accurately measure this.  A greater 
variability in baseline measurement is seen with this sequence.  The GRE MRI 
sequence allows for accurate measurement of T2* may represent a more 
sensitive measure of changes in T2* during cuffing and decuffing.  This is 
highlighted with a more pronounced reactive hyperaemic response as seen in 




Figure 3.2:  Comparison of changes in T2* signal acquired using the EPI (dotted lines) 
and GRE (solid lines) BOLD-MRI sequences in 2 subjects (subject 1 in red and subject 2 
in blue).  ROI’s were drawn in the anterior, lateral, soleus and gastrocnemius muscle 
groups 
 
3.4.3 Arterial Spin Labelling MRI 
A pCASL technique was utilised to acquire perfusion images in one healthy 
volunteer (female, age 24years).  This was a comparison study to look at the 
difference in spatial resolution.  Perfusion maps were generated to show 
changes in perfusion.  Figure 3.3 shows these perfusion maps and the spatial 
resolution attained with the pCASL technique.  Compared to GRE BOLD-MRI 
the spatial resolution is much less.  Perfusion maps show changes with 
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ischaemia after cuff inflation and the subsequent reactive hyperaemia.  The 
maps demonstrate that the pCASL is detecting changes in signal intensity and 
therefore perfusion using ischaemia and reactive hyperaemia model.  Complex 
kinetic modelling was not undertaken as this was a comparative study only, and 
therefore the units if signal intensity in the perfusion maps are in arbitrary units.  
Further modelling can be used to convert this into quantifiable measures of 
perfusion. 
Figure 3.3:  Comparison of GRE BOLD-MRI and pCASL.  A higher spatial resolution is 
achieved with GRE (a) compared with pCASL (b).  Perfusion maps demonstrate change 
in perfusion as measured with pCASL during ischaemia (c) and reactive hyperaemia (d) 
(signal intensity for perfusion maps in arbitrary units) 
 
3.5 Discussion 
BOLD-MRI has traditionally been performed using an EPI sequence weighted 
to be sensitive to T2* due to the rapid image acquisition speeds that can be 
achieved.  The fast image acquisition speed is advantageous in functional 
imaging as it reduces the overall imaging time, and also rapid imaging is 
needed to measure changes in signal after a stimulus120,140,141,168.  In functional 
(a)	 (d)	(c)	(b)	
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BOLD-MRI in the brain the rapid imaging is needed to detect task related brain 
activation.   
The gold standard for acquiring images sensitive to BOLD contrast is GRE MRI, 
as this is the most sensitive to T2* signal changes140,156.  As T2* decay is 
related to inhomogeneities in the local magnetic field this is most sensitive to 
the magnetic susceptibility changes in the magnetic field created by the ratio of 
deoxygenated and oxygenated haemoglobin that forms the basis of BOLD-MRI.  
GRE BOLD-MRI has been not been widely utilised compared to EPI due to the 
lower temporal resolution possible.  Recent advances in hardware and 
processing power of the software, coupled with the higher magnetic field 
strength scanners have helped improve these weaknesses.  This has allowed 
faster acquisition with GRE sequences and sensitivity to BOLD contrast is 
improved by increasing the number of echoes MRI scanners can process.  To 
improve the sensitivity of BOLD-MRI these advances are crucial, as the signal 
changes that are being measured are small167, and this will assist in making this 
image modality more objective and reproducible in the future169. 
Regardless, BOLD-MRI does not produce quantifiable measures of perfusion, 
rather it assesses how perfusion changes in response to a stimulus and this is 
then used as a marker of perfusion.  ASL-MRI is an alternative to BOLD to 
measure perfusion.  This uses water an endogenous contrast agent and 
magnetically labels this proximal to imaging slice.  The change in magnetisation 
can then be used to measure perfusion.  This does require kinetic modelling to 
produce quantifiable measures of tissue perfusion, which lends itself to the 
 104 
introduction of errors.  Also, the signal generated is very small98,102, very much 
like BOLD-MRI.  
In this chapter an optimised method of using BOLD-MRI using a more sensitive 
GRE technique is described.  As already mentioned, GRE is much more of a 
gold standard for measuring BOLD signal due to its increased sensitivity to 
changes in T2* signal.  This has its advantages of more commonly employed 
techniques of EPI-MRI.  It has been demonstrated that the GRE technique 
provides much higher spatial resolution.  This is important in muscle imaging as 
this can help delineate ROI‟s that are confined to muscle, accurately excluding 
areas containing blood vessels, bone and soft tissue.  Accurate placement of 
ROI‟s in muscle, excluding these other areas, improves the sensitivity of the 
BOLD signal measured as T2* changes from other tissue will dilute the muscle 
signal.  As mentioned the signal changes generated from BOLD-MRI are very 
small and therefore T2* signal from non-muscular tissue will very easily dilute 
the signal acquired. 
The GRE BOLD-MRI technique described can also accurately quantify T2* 
signal.  T2* signal is accurately by measuring the decay in signal after the RF 
pulse.  The T2* signal is measured as time taken to reach 67% of the decay.  
The echoes are used to delineate the exponential decay in T2* after the RF 
pulse, with each echo providing a point on the curve.  Therefore the higher the 
number of echoes employed, the more accurately the decay in signal can be 
mapped and subsequently T2* signal quantified (figure 3.4).  Increasing the 
number of echoes come at a cost though, with more processing power required 
to calculate T2*, and also the MRI hardware has limited the amount of echoes 
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that can be utilised.  If more echoes are used then usually this has been at the 
cost of temporal resolution.  BOLD-MRI techniques to date have usually 
employed between 3-5 echoes to measure T2* decay142–144,146,160, whereas the 
novel GRE sequence here has been able to use 14 echoes without loss in 
temporal resolution, with imaging occurring every 3seconds.   
 
Figure 3.4:  Increasing the number of echoes (blue dots) improves the accuracy of 
extrapolating T2* decay and therefore more accurately determining T2* signal 
The improvements in software and hardware, such as using a 32-channel RF 
coil and imaging at higher magnetic fields, have allowed for better spatial 
resolution and accuracy in measuring T2*.  This has helped negate some of the 
benefits concurred with EPI sequences.  The much-improved spatial resolution 
is an important factor when differentiating the superiority of BOLD-MRI in 
comparison with ASL-MRI. The resolution of axial calf images obtained with 
ASL-MRI make it difficult to accurately delineate muscle groups using ROI‟s. It 
should also be noted that both ASL and BOLD-MRI analysis of skeletal muscle 









measurable changes, and in fact even with ASL, it is the changes in perfusion, 
i.e. the changes in the signal intensity time course curves, that are most useful.  
This diminishes the importance of absolute quantification of perfusion in skeletal 
muscle that is possible with ASL but not with BOLD-MRI. 
3.6 Summary 
This part of the study shows that GRE and EPI BOLD-MRI sequences can be 
effectively used to measure perfusion in the lower limb.  EPI has been favoured 
in the past mainly because it allows fast acquisition of images but speed of 
acquisition is becoming less of an issue with modern scanner hardware and 
processing power.  This has allowed GRE, with its better signal to noise ratio, 
spatial resolution and more accurate measurement of T2*, to be increasingly 
favoured over EPI in BOLD-MRI studies.  The improved spatial resolution and 
signal to noise ratio along with no need for complex kinetic modelling means 
that BOLD-MRI has a number of advantages over ASL.  Furthermore, the 
absolute quantification of perfusion in skeletal muscle is much less important in 
the lower limb with the actual perfusion changes in response to provocation 
being much more useful indicator of perfusion.  
For these reasons the GRE sequence was chosen for the subsequent studies 
outlined in this thesis.   
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Chapter 4 
BOLD-MRI Assessment of Perfusion in Patients 
with Critical Limb Ischaemia 
 
4.1 Introduction 
Previous studies have attempted to use BOLD-MRI to assess perfusion in the 
lower limb101,139,142–144,147,153–166.  These studies have shown that it is possible to 
measure changes in lower limb perfusion in healthy controls as well as in 
patients with PAD.  Furthermore these studies have gone on to compare BOLD-
MRI with other surrogate measures of muscle perfusion such as TcPO2144, 
LDF144,154, and VOP139. 
Previous studies using BOLD-MRI have mainly used EPI sequences for 
reasons described before.  We optimised a GRE method for accurately 
quantifying T2* signal in attempt to improve sensitivity and reproducibility.  This 
chapter outlines studies that used this novel GRE BOLD-MRI sequence to 
assess perfusion in young healthy and age-matched controls and compare this 
to patients with CLI. 
4.2 Aims 
(i) To identify which curve parameters are most discriminatory in assessing 
lower limb perfusion using BOLD-MRI. 
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(ii) To use GRE BOLD-MRI to measure changes in perfusion in healthy and 
age-matched controls and compare this to patients with CLI. 
(iii) To assess inter-scan and inter-user reproducibility with GRE BOLD-MRI. 
4.3 Methods 
4.3.1 Study Participants 
Young healthy controls, with an age less the 30years and age-matched controls 
without any evidence of PAD were recruited to the study.  Patients admitted to 
St Thomas‟ Hospital with a diagnosis of CLI were recruited to the study.  ABPI 
was measured in patients with CLI and age-matched controls.  Further details 
are described in chapter 2.2.  
4.3.2 Protocol for BOLD-MRI and Image Analysis 
All subjects followed the protocol for cuffing described in chapter 2.3 and 2.4.   
Both legs were cuffed around the thigh and the same investigator was used for 
cuff inflation and deflation.  The dynamic imaging protocol was the same for all 
subjects (2minutes baseline imaging, cuff then rapidly inflated to 50mmHg 
above systolic pressure and kept inflated for 5minutes during the ischaemic 
phase, cuff rapidly deflated to evoke reactive hyperaemia with imaging for 
5minutes during this phase).  
The MRI imaging protocol and method for reconstructing T2* maps are 
described in chapter 3.3.2.  The GRE sequence was used to measure BOLD 
signal and T2* maps exported to the image analysis software for creation of 
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signal intensity time course curves and measuring curve parameters (see 
chapter 2.6).  ROI‟s were drawn in the 5 muscle groups in the calf (anterior, 
lateral, soleus, gastrocnemius and deep posterior), with a reference T2 
weighted anatomical image acquired in the same region of the calf as imaged 
with GRE BOLD-MRI, for comparison.   
4.3.3 Comparison of controls and patients with CLI 
Both limbs of young healthy and age-matched controls were compared with 
patients with CLI.  For the CLI cohort both the symptomatic limb and the 
contralateral asymptomatic limb were analysed, as a patient control limb, giving 
a four-group comparison (young healthy, age-matched, patient asymptomatic 
and patient symptomatic limbs).  Signal intensity time course curves were 
generated for the 4 groups and curve parameters were compared to determine 
perfusion differences. 
To determine which curve parameters were most discriminatory in detecting 
perfusion with BOLD-MRI, we compared all curve parameters between the 
symptomatic and asymptomatic limbs in CLI patients. These 2 groups were 
chosen because the difference that would be expected between them would be 
the smallest and any parameter that can discriminate between these 2 groups 
would ultimately prove to be the most useful, especially when we use BOLD-
MRI to assess change in perfusion after revascularisation. 
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4.3.4 Inter-user and Inter-scan Reproducibility of GRE BOLD-MRI 
To assess inter-user reproducibility, 2 independent investigators blindly 
analysed the same BOLD-MRI images from both limbs in 7 healthy volunteers 
and signal intensity time course curves and curve parameters were compared. 
Inter-scan reproducibility was investigated with the same blinded user analysing 
BOLD-MRI images from both limbs in repeat scans performed in 5 healthy 
volunteers performed 1-5 weeks apart.  To ensure the same part of the calf was 
imaged, the tibial tuberosity was used as an anatomical landmark and the 
distance between this and the middle of the imaging slice was the same for 
repeat imaging.  Signal intensity time course curves and curve parameters were 
analysed and compared to assess reproducibility between interval scans 
4.3.5 Statistical Analysis 
Statistical analysis was carried out using SPSS v20 (IBM Corp. Armonk, NY, 
USA) and Prism 5 (GraphPad Software Inc. California, USA).  A one-way 
ANOVA (with Tukey Post Hoc test) was used for analysis of curve parameters 
between the healthy and age-matched controls and CLI patient‟s symptomatic 
and asymptomatic limbs, and for differences in ABPI between groups.  Inter-
user and inter-scan reproducibility was assessed using intraclass correlation 
coefficient (ICC), where an ICC >0.9 was deemed as excellent level of 
agreement and Bland Altman analysis.  Analysis of different curve parameters 
to determine the most discriminatory parameters and also for inter-user and 
inter-scan reproducibility was assessed by paired t-test.  Correlation analysis of 
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curve parameters against ABPI was performed using Spearman‟s correlation. 
All values are given as mean ± standard deviation (SD) and P<0.05 was 
deemed to be statistically significant 
4.4 Results 
4.4.1 Subject Demographics 
37 patients with CLI (median age 66years range 37-86), 10 age-matched 
controls (median age 67years range 52-71) and 12 young healthy controls 
(median age 25years range 24-28) were recruited into the study (Table 4.1).  3 
CLI patients were excluded, as they were unable to lie supine for a period long 
enough to undergo BOLD-MRI because of the severity of rest pain.   
 









Age (years, median and 
range) 
25 (24-28) 67 (52-71) 66 (37-86) 
Sex (m:f) 8:4 7:3 29:8 
Smoker 1 1 26 
Hypertension 0 2 29 
Hypercholesterolaemia 0 1 20 
Diabetes 0 0 13 
Rutherford Classification 
   
          IV 
  
22 
          V 
  
9 







The age ranges for the age-matched controls and CLI patients were similar.  
The table also shows the co-morbidities for the subjects recruited.  The CLI 
patients had a higher proportion of smokers, and suffered with hypertension, 
diabetes mellitus and hypercholesterolaemia more than age-matched controls.  
Table 4.1 also highlights the Rutherford classification of CLI in the patient 
group, with 29 patients having Rutherford 4 (rest pain) compared to 9 with 
Rutherford 5 (minor tissue loss) and 6 having Rutherford 6 (major tissue loss).  
There were more males than females in each of the subject groups.  
We compared the ABPI‟s for the age-matched controls and CLI patients groups, 
also comparing the ABPI between the symptomatic and contralateral 
asymptomatic control limbs in CLI patients.  This is shown in figure 4.1.   There 
was a significant difference in ABPI in age-matched controls (1.08 ± 0.04), CLI 
patient‟s asymptomatic limb (0.78 ± 0.18) and CLI patient‟s symptomatic limb 
(0.49 ± 0.14)(P<0.001 for all groups, one way ANOVA, Tukey Post Hoc).  
ABPI was only measurable in 19 of the 34 CLI patients in whom BOLD-CMR 
was performed.  Either calcification in the below knee arteries or absence of a 






Figure 4.1:  Significant difference in ABPI measured in age-matched controls and the 
symptomatic and asymptomatic limbs in patients with CLI (One-way ANOVA, Tukey Post 
Hoc) 
 
4.4.2 Discriminatory Power of Curve Parameters 
Automated curve analysis was performed for the CLI patient cohort and all the 
curve parameters were compared between the symptomatic and asymptomatic 
limbs.  The curve parameters that were analysed are described in chapter 2.6 
and figure 2.6, but in brief they are; Baseline T2* signal before cuffing, Time to 
half ischaemia (THIM), T2* at the end of cuffing (T2*Min), Signal reduction in 
ischaemia (SRi), Gradient of reactive hyperaemia (Grad), Time to peak (TTP), 
Maximum T2* in reactive hyperaemia (T2*Max) and Baseline T2* after reactive 
hyperaemia. 
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Comparing the 2 limbs in CLI patients, 3 parameters were found to be most 
discriminatory in distinguishing between the two.  Grad was found to be 
significantly higher in the asymptomatic patient control limb compared to the 
ischaemic limb (0.28 ± 0.14 ms/s vs. 0.17 ±0.11 ms/s, p<0.0001).  Similarly, SRi 
was significantly higher in the asymptomatic control limb (11.03 ± 5.62% vs. 
8.68 ± 5.11%, p<0.0001).  T2*Min was also found to be significantly different 
between the 2 limbs (21.99 ± 3.63 ms vs. 22.80 ± 3.62 ms, p<0.01).  None of 
the other parameters were significantly different between the 2 limbs in CLI 
patients (Table 4.2).  For all subsequent perfusion comparisons between 










Grad(ms/s) 0.28±0.14 0.17±0.11 p<0.0001 
SRi(%) 11.03±5.62 8.68±5.11 p<0.0001 
Minimum T2*(ms) 21.99±3.63 22.80±3.62 p<0.01 
Baseline (Start)(ms) 24.70±4.09 25.04±3.92 p=0.16 
Baseline (End)(ms) 24.64±4.07 24.85±3.93 p=0.43 
Maximum T2*(ms) 24.93±4.25 24.56±3.93 p=0.20 
TTP(seconds) 68.7±22.76 64.5±29.7 p=0.14 
THIM(seconds) 205.5±78.3 195.5±81.5 p=0.24 
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4.4.3 BOLD-MRI T2* Signature in the Ischaemic Limb Compared with 
Controls 
Comparison of the BOLD-CMR T2* signal intensity curves from the limbs of 
young control subjects, age-matched controls, and CLI patients generated for 
each of the 5 muscle groups, demonstrated a clear difference between 
ischaemic limbs and control limbs, with the soleus musculature generating the 
most distinctive curve characteristics (Figure 4.2).  In all groups there was a fall 
in T2* signal after cuff inflation during the ischaemic phase, but the signal for 
the ischaemic limbs plateaued sooner than the other groups and the total 
reduction in signal intensity was much less.  During reactive hyperaemia the 
rise in T2* signal was faster in the young controls and most delayed in the 
ischaemic limbs of the CLI patients.  A significantly lower Grad was measured in 
the ischaemic limb (0.17 ± 0.11ms/s) compared with the patient contralateral 
(0.28 ± 0.14ms/s, p<0.001), age matched (0.38 ± 0.17ms/s, p<0.001) and 
young control limbs (0.47 ± 0.16ms/s, p<0.001, Figure 4.3).  Similarly, the SRi 
was lower in the ischaemic limb (8.68 ± 5.11%) compared with the patient 
contralateral (11.03 ± 5.62%, p<0.001), age-matched controls (13.77 ± 6.33%, 
p<0.001) and young controls (14.07 ± 5.09%, p<0.001, Figure 4.4).  No 
relationship was seen with regards to BOLD derived parameters and duplex or 
angiographic extent of disease. 
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Figure 4.2:  T2* signal intensity time course curves for young healthy and age-matched 












































































































Figure 4.4:  Difference in signal reduction in ischaemia between the 4 groups (One-way 




Curve parameters of Grad and SRi were compared with ABPI to see if any 
correlation existed between the BOLD-MRI derived perfusion parameters and 
the traditional method of grading ischaemia.  No correlation (Spearman‟s 
Correlation) was seen between ABPI and Grad (r=0.34, p=0.20,) or with SRi (r-
0.07, p=0.80)(Figure 4.5).  
 
Figure 4.5:  Correlation of ABPI with BOLD-MRI parameters of Grad (A) and SRi (B) 
(Spearman’s Correlation) 
 
Patients with CLI had multiple level disease, and it is difficult to draw correlation 
with extent of arterial disease and BOLD-MRI derived parameters as this 
sequence only allows imaging at a single level in the calf. 





























4.4.4 Subgroup Analysis in CLI Patients 
In CLI patients, a subgroup analysis was performed to assess differences due 
to age, smoking and diabetes.  Signal intensity time course curves were 
generated and compared for each groups, as well as automated analysis of the 
curve parameters Grad and SRi. 
For analysis of difference in age, CLI patients under the age of 65years (n=13) 
were compared to over those 65years or above (n=21).  Differences were seen 
in the signal intensity time course curves.  Analysis of curve parameters showed 
a significant difference for Grad (<65years 0.21 ± 0.12ms/s vs. ≥65years 0.14 ± 
0.1ms/s, p<0.005, unpaired t-test) and SRi (<65years 10.41 ± 5.04% vs. 7.69 ± 
5.08, p<0.005, unpaired t-test)(Figure 4.6). 
 
Figure 4.6:  Age related (<65 years vs. ≥65years) change in CLI Patients. Difference seen 
in signal intensity time course curves (A), Grad (B) and SRi (C) (unpaired t-test). 
 
Investigating differences between based in smoking history and diabetes did 



















































(n=8) Grad was 0.17 ± 0.11ms/s vs. 0.14 ± 0.11ms/s, and SRi was 8.80 ± 
5.31% vs. 8.43 ± 4.31% (p>0.05, unpaired t-test for both).  Similar signal 
intensity time course curve are generated between the 2 groups (Figure 4.7).   
 
Figure 4.7:  Comparison of smoking history, with no difference in signal intensity time 
course curves (A), Grad (B) and SRi (C) (unpaired t-test). 
 
Figure 4.8:  Comparison of diabetic history, with no difference in signal intensity time 
course curves (A), Grad (B) and SRi (C) (unpaired t-test). 
 
Comparing diabetics (n=13) versus non-diabetics (n=21), signal intensity time 





































































































and SRi 8.01 ± 4.38% vs. 9.04 ± 5.52% (p>0.05, unpaired t-test for both)(Figure 
4.8).  
 
4.4.5 Inter-user and Inter-scan Reproducibility of BOLD-MRI 
2 blinded, independent investigators analysing BOLD-MRI with the automated 
analysis software in 7 young healthy volunteers, assessed inter-user 
reproducibility. There was good reproducibility as evidenced by strong 
correlations for both Grad and SRi measurements (ICC = 0.99 (95% CI 0.98-
0.99) and 0.99 (95% CI 0.98-0.99), respectively, p<0.0001 for both, Figure 4.9).  
Bland Altman analysis concurred with ICC (Grad: mean bias -0.002 (95% limits 
of agreement -0.05-0.05, SRi: mean bias -0.04 (95% limits of agreement -1.79-
1.70), Figure 4.10).  Similar T2* curves were generated by the two users.  No 
significant difference was found between Grad and SRi measured by each of 
the 2 investigators (Figure 4.11).  
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Figure 4.9:  Intraclass correlation coefficient for assessing intra-user reproducibility for 
Grad (A) and SRi (B) 































































Figure 4.11:  Example T2* signal intensity time course curves generated by the 
automated analysis software program showed good reproducibility between user.  The 
table shows no significant difference in Grad and SRi as measured by the 2 users (paired 
t-test) 
 
5 young healthy volunteers underwent repeat BOLD-MRI imaging 1-5 weeks 
apart and serial scans were analysed by a single investigator to assess inter-
scan reproducibility.  There were excellent correlations for Grad and SRi 
between scans in the same subject (ICC = 0.95 (95% CI 0.90-0.98) and 0.96 
(95% CI 0.90-0.98) respectively, p<0.0001 for both, Figure 4.12).  Bland Altman 
analysis confirmed good reproducibility between scans for Grad (mean bias 
0.0004 (95% limits of agreement -0.14-0.14)) and SRi (mean bias -0.92 (95% 
limits of agreement -4.88-3.04), Figure 4.13).  No significant difference was 
found between Grad and SRi between interval scans for all muscle groups 
analysed (Figure 4.14).  

















User	1 User	2 p	values 
Grad (ms/s) 0.47±0.15 0.47±0.15 p>0.05 
SRi (%) 14.54±4.42 14.45±4.45 p>0.05 
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Figure 4.12:  Interclass correlation coefficient for assessing reproducibility between 
interval scans for Grad (A) and SRi (B) 
 
 





























































Figure 4.14:  Example T2* signal intensity time course curves for the same subject 
scanned on 2 separate occasions.  The table shows no significant difference for Grad 
and SRi between interval scans in the same subjects (paired t-test) 
 
4.5 Discussion 
In this study, a novel BOLD-MRI method using a GRE sequence more sensitive 
to T2* signal was used to identify changes in muscle perfusion in the calf as a 
result of arterial occlusion and subsequent reactive hyperaemia.  This method 
builds on previous studies investigating muscle perfusion using BOLD-
MRI101,139,142–144,147,153–166.   
As already mentioned earlier, provocation testing is required to produce 
measurable changes in muscle perfusion.  It is the changes as a result of these 
stimuli that produce measures that can be used to assess perfusion.  What is 
not known is what measures are the best to assess muscle perfusion.  The 
changes in perfusion represent a physiological response to changes in demand 
and ability to perfuse muscle.  Similarly, provocation testing in the form of stress 
and treadmill testing is used in assessing cardiac perfusion, but this is different 
to the cuffing model used in this study.  Cuffing induces ischaemia in muscle, 

















Scan	1 Scan	2 p	values 
Grad (ms/s) 0.46±0.17 0.46±0.16 p>0.05 
SRi (%) 13.97±5.42 14.88±5.22 p>0.05 
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whereas in cardiac testing there is a functional change in the myocardium that 
requires increased perfusion.  Nevertheless, the results are similar in that it 
results in a hyperaemic response.  
This study has imaged the largest cohort of patients with limb ischaemia (n=37) 
with BOLD-MRI and compared them to young healthy, and age-matched 
controls.  Compared to previous studies using BOLD-MRI in PAD 
patients142,143,161, this is the first study to investigate patients with CLI, in whom 
the risk of limb loss is considerably higher1,3.  Previous studies have looked at 
patients with IC, a more stable and mild form of PAD, which does not always 
require or warrant intervention.  
4.5.1 Discriminatory Power of T2* Signal Changes 
Two new parameters, Grad and SRi, were developed and tested for 
assessment of changes in perfusion, measured by T2* signal changes on 
BOLD-MRI.  Both Grad and SRi allowed reliable, automated analysis of limb 
perfusion.  Curve parameters used in previous BOLD-MRI studies include TTP, 
T2*Max, T2*Min and THIM142,143,146,160,161,164 but we found Grad and SRi to be 
superior.  Grad can be thought analogous to TTP and T2*Max.  It calculates the 
maximum slope of the curve during reactive hyperaemia.  As it is calculated 
from the mean of the 10 highest values measured from the first derivative of T2* 
signal from cuff deflation to T2*Max, it overcomes some of the weakness of 
using TTP and T2*Max as the inherent background signal noise can interfere 
with the BOLD signal.  SRi is calculated as a percentage drop in signal form 
initial baseline T2* until the end of the ischaemic phase.  Again the inherent 
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noise can influence the actual points that measured for these parameters.  Also 
signal intensity time course curves are usually normalised to allow for the 
variation seen in T2* signal that occur between subjects, making direct 
comparison of T2* values difficult to interpret.  The new parameters overcome 
this by using parameters that are dependent on the change in T2* signal rather 
than actual signal values.  
Lack of reproducibility has been cited as a potential weakness of BOLD-MRI155.  
A number of reasons could account for this and are discussed in more detail 
later, but one reason could be related to how curve parameters are derived.  As 
alluded to before, the actual BOLD signal generated is very low and difficult to 
distinguish and measure over the inherent signal noise from MRI scanners167.  
The noise makes the defining points along the curve difficult.  Some of this is 
overcome by smoothing of curves to diminish the influence of background 
interference.  Also, particularly in patients with PAD, the overshoot in reactive 
hyperaemia is dampened and in some cases completely absent.  This is 
particularly the case as the severity of ischaemia increases, which makes 
identifying the exact point of the peak more difficult to define and therefore 
parameters such as T2*Max and TTP are prone to more errors. 
The new parameters identified here overcome many of this weakness allowing 
for more reliable assessment of perfusion. The 2 parameters also interrogate 
different aspects of the curve.  SRi assesses the ischaemic phase, measuring 
the drop in signal intensity.  Grad, on the other hand looks at the response to 
reactive hyperaemia.  Both would be expected to be impaired in the presence of 
PAD and therefore provide useful indication of both physiological reserve and 
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the ability to responds after the stress has been removed, i.e. reactive 
hyperaemia170. 
Both Grad and SRi were investigated in the CLI patients, comparing the 
ischaemic limb with the contralateral asymptomatic control limbs.  The most 
sensitive marker of perfusion would ideally be able to reliably distinguish 
between ischaemic and non-ischaemic muscle in the same limb.  Investigating 
the ischaemic limb and comparing this with the asymptomatic limb  was chosen, 
as these 2 groups would be expected to show the smallest difference in 
perfusion to the muscle between limbs.  The ischaemic limbs had a lower Grad 
and SRi compared the contralateral control limbs in CLI patients.  T2*Min was 
also significantly different between the 2 limbs in CLI patients, but the difference 
was just significant and as it represents an absolute T2* value and is almost 
analogous with SRi, it was decided that the best parameters to go forward with 
were SRi along with Grad. 
4.5.2 BOLD-MRI Assessment of Perfusion in CLI 
This study has shown consistent changes in the curve profiles in patients with 
CLI compared to their own contralateral asymptomatic limb and with age-
matched and young healthy controls.  The signal intensity time course curves 
show a graduated response as the level of arterial disease increases.  This is 
highlighted in the curve parameters that are measured.  It would be safe to 
surmise that young healthy controls would be expected to have the best 
perfusion profiles and this is confirmed with BOLD-MRI derived parameters, 
with them having a higher Grad and SRi, compared to age-matched controls 
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and CLI patients.  Similarly, age-matched controls have better signal intensity 
time course curves compared to CLI patients.  Even in CLI patients, the 
asymptomatic contralateral control limbs have better perfusion profiles 
compared then the symptomatic ischaemic limbs.  Patients with CLI almost 
always have evidence of disease in the contralateral limb171 and therefore the 
fact that the profiles determined with BOLD-MRI show a graduated response in 
the different groups highlights that it may indeed be sensitive to the degree of 
severity of limb ischaemia. 
The signal intensity time course curves demonstrated in this study are similar to 
previous studies140,141, in that at baseline T2* signal is steady.  The initiation of 
arterial occlusion by thigh cuff inflation to suprasystolic pressures results in a fall 
in T2* signal.  This is most pronounced in healthy young volunteers, and the 
decrease is the least in the CLI patient‟s ischaemic limbs.  The onset of reactive 
hyperaemia, after cuff deflation, results in a rise in T2* signal but again this is 
different between the groups.  The ischaemic limbs show a more gradual 
increase, taking longer to reach a peak compared to the other groups, with 
much less of an overshoot.  This is reflected in the curve parameters acquired 
from the different groups.   
ABPI is currently used for confirming the diagnosis of PAD and for assessing 
improvements in blood flow to the foot after revascularisation.  Unlike BOLD-
MRI, ABPI cannot, however, be measured in all patients.  This is reflected in the 
results of the present study, where we were unable to measure ABPI in just 
over 40% of the patients with CLI.  There was no correlation between ABPI 
values and corresponding Grad or SRi, the former measuring global blood flow 
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into the limb rather than perfusion at tissue level.  ABPI measure pressure in the 
leg and it would suggest that BOLD-MRI derived assessment of perfusion is to 
be believed then there are further processes that occur in determining 
perfusion.  Pressure measurements reflect only the inflow of blood into the limb, 
but do not take into account the physiological processes that are occurring at 
cellular level in muscle perfusion.  It could be that BOLD-MRI derived 
assessment of muscle perfusion takes this into account as it assessing the ratio 
of oxygenated and deoxygenated haemoglobin in muscle tissue.  It should be 
noted, however, that the combination of clinical examination and ABPI remain a 
practical, simple and useful tool for the initial assessment of the critically 
ischaemic limb. 
Ageing effects have been described previously when using BOLD-MRI146,147,172.  
This study has confirmed these findings, with younger CLI patients having a 
better perfusion profile compared to older patients.  No difference is seen when 
investigating smoking history and diabetes.  Age related change in perfusion 
are well established173–175, and are postulated to be related to an increase in 
vascular disease burden along with loss in muscle mass and change in muscle 
fibre type.  This leads to a reduced physiological reserve in muscle perfusion 
and this may explain the age related changes measured with BOLD-MRI, even 
in the face of PAD. 
Patients with diabetes have been investigated with BOLD-MRI and differences 
in perfusion profiles have been detected176.  However, this study compared 
diabetics with age-matched controls without evidence of PAD.  Another study 
failed to show any difference between diabetics and non-diabetics172.  In this 
 132 
study the influence is PAD is certainly compounding any differences due to the 
presence of diabetes, and making any conclusion on the influence of diabetes 
is impossible.  Smoking affects on BOLD-MRI have not been demonstrated 
previously, and this study does not show a difference. 
4.5.3 Reproducibility of Novel GRE BOLD-MRI 
Failure to show reliable reproducibility of BOLD-MRI has been cited as a major 
weakness of this imaging modality155.  They‟re maybe a number of factors that 
result in this lack of reproducibility.  The accuracy of T2* signal acquisition is 
major factor, and can be improved in a number of ways.  Imaging with higher 
magnetic field scanners improves the BOLD signal127,160, along with 
improvements in other MRI hardware, such as RF coils.  The use of GRE 
sequences compared to EPI improves the spatial resolution, allowing for 
accurate exclusion of major blood vessels, bone and other soft tissue, which 
avoids erroneous T2* quantification caused by inadvertent inclusion of these 
structures.  Increasing the number of echoes result in more accurate 
quantification T2*.  These factors will improve the sensitivity of BOLD-MRI, 
which should aid reproducibility.   
The study which highlighted the weakness in the reproducibility of BOLD-MRI 
was by Versluis et al155.  The lack of reproducibility they have reported may well 
be due to a number of reasons.  Firstly, they imaged at 1.5T reducing the 
amount of BOLD signal detected.  Also they used a lower resolution EPI 
sequence with a small of number of echoes (number of echoes=6).  This would 
have reduced the accuracy of T2* signal detected.  Finally, their image analysis 
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was conducted with a single ROI incorporating the whole calf, including blood 
vessels and soft tissue (but excluding bone), which would have resulted in 
erroneous assessment of T2*.  Furthermore, they analysed only 2 parameters 
for the assessment of reproducibility, namely T2*Max and TTP, but they do not 
mention how these parameters were calculated, whether this was done 
manually or in an automated fashion.  These limitations in that study may have 
resulted in their findings of a lack or reproducibility. 
Conversely, this study has demonstrated a number of developments, with the 
aim of improving reproducibility, such as imaging at higher field strengths (3T 
versus 1.5T), improved spatial resolution with GRE sequences, more accurate 
quantification of T2* achieved by using more echoes (14 in total), better 
delineation of ROI‟s to accurately exclude non-muscular tissue, and using 
automated analysis of curve parameters and parameters that are more reliably 
defined and measured.  These improvements have been shown to improve the 
reproducibility using the novel GRE sequence in combination with better MRI 
scanners and hardware, and careful delineation of ROI‟s and automated 
analysis of curve parameters.  The study has shown excellent reproducibility 
both between different users and also between scans in the same subject to the 
curve parameters we have established are the most important in the 
assessment of perfusion using BOLD-MRI.   
Further improvement in the future will only aid in increasing the sensitivity and 
accuracy of BOLD-MRI, which should result in even more reliable assessment 
of perfusion with this modality.  The introduction of higher magnetic field 
strength scanners is very near on the horizon, coupled with improvements in 
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scanner hardware, such as gradient coils and RF coils will accelerate these 
developments.  Also, the processing power of software used in MRI is 
increasing allowing more complex sequences to be utilised, which would not 
have been possible in the past.  The notion that BOLD-MRI is not reproducible, 
and therefore not suitable as clinical tool, can be considered no longer true as 
shown with the results of this study. 
4.6 Summary 
BOLD-MRI performed with the novel GRE sequence can detect perfusion 
differences between ischaemic limbs and control limbs.  The modality is 
sensitive enough to detect incremental changes in perfusion, as represented by 
the different cohorts investigated.  Automated analysis of curve parameters has 
the potential to reduce errors, which may impact on the reliability and objectivity 
of this technique.  Furthermore, assessing the change in T2* signal may prove 
to be more useful then absolute values, with the introduction of 2 new 
parameters identified as most discriminatory in detecting differences in 




Assessment of Perfusion After Lower Limb 
Revascularisation  
5.1 Introduction 
Patients with CLI are at significant risk of major limb loss1,3, and therefore 
revascularisation is undertaken with the aim of salvaging the limb.  Interventions 
include surgical and/or endovascular revascularisation.  Patients with PAD, 
particularly those with CLI, usually have disease at multi-levels, with 
interventions performed in stepwise basis.  The most proximal lesions are dealt 
with first, and more distal disease intervened on as required.  Improvement in 
tissue perfusion is the most important determinant of limb salvage in critically 
ischaemic limbs that are revascularised using bypass surgery or 
angioplasty/stenting, but there is currently no reliable method for measuring the 
adequacy of perfusion in the lower limb52.   
Apart from assessment of clinical signs and symptoms, the only method widely 
employed in demonstrating the success of revascularisation is measuring the 
ABPI, but this may not be possible in all patients.  ABPI is, in any case, a 
surrogate for lower limb perfusion and the absolute measures of sufficient 
revascularisation are clinical endpoints such as symptom improvement and 
tissue healing.  These endpoints maybe easier to define in patients with IC or 
rest pain, as improvement in symptoms can readily be assessed, but tissue 
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healing usually only becomes apparent after a number of weeks and, for 
patients who may require more extensive revascularisation, a window of 
opportunity to improve tissue perfusion expediently would be lost resulting in 
amputation177–179. 
Having a method to rapidly and reliably assess the changes in perfusion after 
intervention would aid in the management of patients with CLI.  It would allow 
for assessment of the adequacy of revascularisation, and help identify those 
patients where perhaps the further procedures are needed to fully optimise 
perfusion.   
In the previous chapter, it was shown that the novel GRE BOLD-MRI sequence 
developed was able to accurately differentiate perfusion in patients with CLI 
against controls.  Moreover, it was sensitive enough to distinguish between the 
symptomatic and asymptomatic limbs in CLI patients.  If BOLD-MRI could also 
be used to provide information on changes in perfusion after revascularisation it 
may prove a useful adjunct in the management of patients with CLI. 
5.2 Aims 
(i) To use BOLD-MRI to assess changes in perfusion in patients with CLI before 
and after revascularisation. 




5.3.1 Study Participants 
Patients with CLI were imaged prior to and 1 to 14 days (median 3 days) after 
revascularisation with the GRE BOLD-MRI sequence.  Intervention involved 
endovascular and/or open surgery of the aortic, iliac, common femoral or 
superficial femoral arteries (SFA).  Patients undergoing distal bypass were 
excluded because of a possible risk of graft occlusion with cuffing and because 
haematoma secondary to open surgical intervention below the knee made 
interpretation of BOLD-CMR scans difficult.  Successful revascularisation of the 
target vessels was confirmed by duplex and/or CT angiography, and related to 
ABPI measured before and after intervention.  
Further details of study participants and consent process in described in chapter 
2.2. 
5.3.2 Protocol for BOLD-MRI and Image Analysis 
All subjects underwent imaging using the MRI setup and cuffing protocol 
described in chapter 2.3 and 2.4.  The GRE sequence described in chapter 
3.3.2 was used and image analysis carried out as described in chapter 2.6 
using the automated analysis software.   
5.3.3 T2* Signal Changes With Revascularisation 
Patients with CLI were imaged with the GRE BOLD-MRI sequence.  T2* maps 
were analysed and the signal intensity time course curves were compared 
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before and after revascularisation.  Comparison with CLI patients contralateral 
control limbs was also performed to assess the improvement in perfusion after 
intervention.  The most discriminatory curve parameter‟s, i.e. Grad and SRi, 
determined before and after revascularisation were compared as was the 
change in ABPI. 
5.3.4 Sensitivity of BOLD-MRI to Incremental Changes in Perfusion 
To determine whether BOLD-MRI was sensitive to incremental changes in 
blood flow, the fold change in Grad and SRi after revascularisation was 
compared between patients in whom the SFA was patent after intervention and 
those in whom the SFA remained occluded.  Not all CLI patients underwent 
interventions to recanalise the SFA, as dealing with more proximal disease was 
more severe and required intervention first.  The fold change in ABPI was also 
measured and compared to the fold change in curve parameters. 
Fold change in curve parameters and ABPI was calculated by dividing the post 
intervention value by the pre revascularisation value.  Using fold change it was 
possible to determine if the patency of SFA had a measurable impact on the 
change in curve parameters compared to changes in ABPI.  A fold change of >1 
indicates that there was an improvement after revascularisation, whereas a fold 
change of <1 indicates the opposite. 
5.3.5 Statistical Analysis 
Statistical analysis was carried out using SPSS v20 (IBM Corp. Armonk, NY, 
USA) and Prism 5 (GraphPad Software Inc. California, USA).  Analysis of pre 
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and post intervention changes in curve parameters (Grad and SRi) and ABPI 
was carried using a paired t-test.  Correlation of fold change in ABPI compared 
to Grad and SRi was performed with Spearman Correlation.  The fold change in 
the same curve parameters and ABPI was compared in patients who had a 
patent SFA and those in whom it was occluded using a Mann Whitney Test.  All 
values are given as mean ± SD and p<0.05 was deemed to be statistically 
significant. 
5.4 Results 
5.4.1 Subject Demographics 
13 patients with CLI were imaged before and after successful revascularisation. 
One patient was excluded due to the presence of significant oedema in the calf 
on pre and post intervention imaging interfering with accurate measurement of 
T2* signal.  The lateral compartment was excluded in one patient due to loss of 
signal from coil artefact.   
Table 5.1 shows the patients imaged for this study along with their respective 
interventions.  It highlights that ABPI was only measurable in 5 patients pre 
intervention and 8 patients after revascularisation.  9 patients had Rutherford 
class 4 disease (rest pain), whilst the remaining 4 had Rutherford 5 disease 
(tissue loss).  Mean follow up was 11 months (range 1-19months).  Rest pain 
was resolved in all patients, and successful tissue healing was evident in all but 
1 patient, who required bypass surgery after occlusion of their SFA stent 3 
months post intervention. 
Table 5.1:  Demographics, extent of disease and ABPI measurements of CLI patients imaged before and after revascularisation, along with their 
outcomes and follow-up.
  
Sex Age Rutherford Disease ABPI Pre ABPI Post Procedure Outcome  Follow up 
















5 M 79 5 CIA/EIA occlusion +++ 
++
+ 








7 M 65 4 EIA stenosis, CFA occlusion 0.22 0.7 





8 M 79 4 EIA/CFA/SFA occlusion +++ +++ 

















12 M 75 5 EIA stenosis, SFA occlusion 0.58 0.95 Iliac stenting & SFA angioplasty 




13 M 59 5 EIA/SFA occlusion 0.38 0.53 
Femoral endarterectomy & Iliac/SFA angioplasty 
& stenting 
Stent occlusion 
needing bypass  
17 months 
5.4.2 Changes in Perfusion Pre & Post Revascularisation 
T2* signal intensity time course curves in the ischaemic limb prior to 
intervention were consistent with curves typical of limbs with impaired perfusion 
(Figure 5.1).   
 
Figure 5.1:  T2* signal curve for ischaemic limbs pre and post revascularisation (n=12), 


































































































A significantly lower Grad and SRi confirmed this in the pre intervention 
ischaemic limbs compared to contralateral asymptomatic control limbs (Grad: 
0.14 ± 0.10ms/s vs. 0.28 ± 0.14ms/s, p<0.0001 and SRi: 8.08 ± 5.04% vs. 
11.03 ± 5.62%, p<0.005, unpaired t-test), and age-matched controls (Grad: 0.38 
± 0.17ms/s, p<0.0001 and SRi: 13.77 ± 6.33%, p<0.0001, unpaired t-test). 
 
Figure 5.2:  Changes in Grad after revascularisation (paired t-test) 
 
Repeat BOLD-MRI after successful revascularisation, resulted in improvement 
in T2* signal intensity time course curves to resemble the perfusion profiles of 
CLI patients contralateral asymptomatic control limbs (Figure 5.1).  Assessment 
of curve parameters showed a significant increase in Grad (Figure 5.2) and SRi 
(Figure 5.3) after revascularisation (Grad: 0.14 ± 0.10ms/s vs. 0.32 ± 0.18ms/s, 














































(n=59) (n=59) (n=59) (n=59) 
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Figure 5.3:  Change in SRi after revascularisation (paired t-test) 
ABPI changes before and after revascularisation were also compared in those 
patients where it was measurable.  A significant improvement was seen in ABPI 
after intervention (0.42 ± 0.14 vs. 0.76 ± 0.22, p<0.01, unpaired t test)(Figure 
5.4). 
 




























































































































































Fold change in ABPI after successful revascularisation was correlated with fold 
change in Grad and SRi (Figure 5.5).  No correlation was seen between ABPI 
and Grad (r=0.05, p>0.05, Spearman‟s Correlation) or with SRi (r=0.07, p>0.05, 
Spearman‟s Correlation). 
 
Figure 5.5:  Correlation of ABPI fold change with Grad and SRi (Spearman’s Correlation) 







































5.4.3 Sensitivity of BOLD-MRI to Incremental Changes in Perfusion  
The extent of arterial disease was assessed in patients undergoing intervention.  
Not all patients had a patent SFA post revascularisation, as in some cases 
more proximal lesions were tackled to improve perfusion.  Of the 12 patients 
undergoing intervention that could be assessed reliably with BOLD-MRI the 
patency of SFA after revascularisation was examined, and the changes in curve 
parameters dependent on this was analysed. 
9 CLI patients had a patent SFA after revascularisation, whether the SFA was 
patent prior to intervention, or intervention included treating the SFA.   In 3 
patients the interventions were concentrated on tackling more proximal lesions, 
such aorto-iliac or common femoral artery disease, and after revascularisation 
the SFA remained occluded. 
The fold change in Grad and SRi were compared depending in the patency of 
the SFA.  Patients in whom the SFA was patent demonstrated a larger-fold 
increase in Grad compared with those in whom the SFA remained occluded 
after proximal revascularization (3.49 ± 2.56 vs. 1.87 ± 0.73; p < 0.05).  A 
similar trend was observed for SRi (3.12 ± 6.16 with patent SFA vs. 1.81 ± 1.27 
with occluded SFA; p > 0.05).  Patency of the SFA had no significant effect on 
the fold change in ABPI after intervention (2.56 ± 1.61 with patent SFA vs. 2.86 
± 0.49 with occluded SFA; p > 0.05)(Figure 5.5), in those CLI patients where it 





Figure 5.5:  Fold Change in Grad (A), SRi (B), and ABPI (C) after revascularisation 
depending on the patency of the SFA (Mann Whitney Test) 




























































Having shown that the novel GRE BOLD-MRI sequence developed in this study 
can reliably differentiate between ischaemic limbs and control limbs in the 
previous chapter, the next step undertaken was to assess perfusion changes in 
CLI patients undergoing revascularisation.   
5.5.1 Measuring Perfusion Changes after Revascularisation 
In this study we have shown that BOLD-MRI can detect changes in perfusion 
after intervention.  It can be seen that the T2* signal intensity time course 
curves from the ischaemic limbs in CLI patients prior to intervention are 
consistent with curves expected for limbs with poor perfusion.  After successful 
revascularisation, the curve profiles change to resemble curves generated from 
asymptomatic limbs.  This is confirmed by the change seen in curve parameters 
calculated and a significant improvement is seen in both Grad and SRi, with the 
values comparable to the contralateral, asymptomatic (control) limb in patients 
presenting with CLI 
All patients underwent successful revascularisation, confirmed by improvements 
in clinical symptoms, and a rise in ABPI in those patients where ABPI was 
measurable. One patient did require further revascularisation, but this was 
3months after their initial intervention and was due to stent occlusion.  In this 
particular intervention the post-intervention BOLD-MRI carried out 1 week after 
intervention demonstrated that the perfusion had been improved by the 
revascularisation undertaken, and it was only 3months later did the stent 
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occlusion occur requiring further procedures.  Up to that stage that patient had 
seen improvement in their symptoms.  One further patient was found to have in-
stent stenosis at follow-up imaging, but again at the time of post-intervention 
BOLD-MRI, their perfusion had been improved as evidenced by clinical 
symptoms and change in ABPI. 
Only one study previously has attempted to investigate the role of BOLD-MRI 
before and after intervention in patients with PAD143.  This study investigated 10 
patients with IC undergoing SFA angioplasty and used BOLD-MRI with an 
ischaemia-reactive hyperaemia model to evoke changes in perfusion, however 
they only analysed the reactive hyperaemia portion of the curve.  They showed 
a trend towards improved perfusion as indicated by change in parameters, but 
failed to show any significance with their technique or with the parameters they 
chose to evaluate perfusion.  They did have a number of limitations in their 
study, as alluded to in previous chapters.  This study was performed with 1.5T 
MRI scanner and using an GE EPI sequence with only 4 echoes making 
accurate quantification of T2* signal more difficult.  They did show a significant 
improvement in patients ABPI‟s post intervention, suggesting that although 
BOLD-MRI was not sensitive enough to detect significant changes, the 
revascularisation performed was sufficient to improve perfusion. 
This study is the first that has demonstrated that with the novel GRE BOLD-MRI 
sequence improvement in perfusion can reliably be detected.  Utilising improved 
scanner technology and MRI sequences, along with improved image analysis, it 
has been shown that the impact of interventions can be immediately assessed 
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for adequacy with BOLD-MRI.  This study has used the largest cohort to date to 
assess changes in perfusion after revascularisation with BOLD-MRI. 
ABPI is widely utilised as a measure of adequacy of perfusion1,3,52.  After 
revascularisation, an improvement in ABPI of >0.10 provides an indication if 
interventions have resulted in increasing blood flow to the limb180.  ABPI is not 
measurable in every patient with PAD, such as with very calcified arteries.  Also 
it can be difficult to accurately measure in patients with severe ischaemia, as 
encountered in CLI, where very low flow in the tibial vessels can be difficult to 
accurately detect.  Variability in ABPI measurement and technique can also be 
problematic when using this technique16,181.   
This study confirms that successful revascularisation was performed not only by 
improvements in clinical symptoms, but also by post-procedure imaging and 
also by improvement in ABPI by >0.10.  This improvement is also seen in 
perfusion measurement with the novel GRE BOLD-MRI technique.  However, 
as seen in chapter 4, no correlation is seen with the improvement seen in ABPI 
after successful revascularisation and changes in BOLD-MRI derived perfusion 
measures.  Therefore, it suggests that ABPI and BOLD-MRI derived measures 
are assessing different aspects of blood flow and perfusion in the limb.  ABPI is 
a measure of pressure related changes in the limb, and such is dependent on 
the “inflow” of blood to the limb.  It does not take into account the microvascular 
status of perfusion in the tissue.  
Some of the changes in the curve characteristics can be attributed to the 
increased inflow of blood into the limb.  The increase in SRi after 
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revascularisation seen could be related to the increase in inflow into the limb 
after intervention.  This increased inflow would result in a greater reserve the 
muscles can accommodate during the ischaemic phase.  The improved Grad 
can also be related to the improved inflow after the cuff is deflated to evoke 
reactive hyperaemia.  
5.5.2 Incremental Changes in Perfusion After Revascularisation 
An imaging modality that allows for sensitive assessment of perfusion would 
greatly assist in the management of patients with CLI.  These patients usually 
have arterial disease at multiple levels and formulating a management plan can 
be challenging as it can be difficult to quantify the contribution each disease 
level has.  For these patients, the most proximal disease is tackled first, but this 
may not be enough to adequately improve perfusion to salvage the limb1,3. An 
early objective assessment of the extent of improvement in limb perfusion after 
proximal revascularisation may help identify patients that need prompt 
revascularisation of the distal vasculature thereby improving limb salvage. 
This study has shown that not only is the novel GRE BOLD-MRI sequence 
sensitive to changes in perfusion after successful intervention, but it is also able 
to detect perfusion changes depending on the status of the inflow.  The main 
inflow vessel into the calf is the SFA.  In some CLI patients, interventions were 
performed on more proximal vessels, i.e. aortic, iliac and/or common femoral 
artery, with the SFA occluded.  In other patients, the SFA was either patent and 
more proximal lesions were intervened on, or that the SFA itself was 
revascularised in addition to treating the proximal disease.  A greater fold 
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change in Grad was observed in cases where the SFA was patent after 
intervention. A similar trend was seen for SRi but the differences did not reach 
significance.  The fold change in ABPI, however, was not associated with the 
patency of the SFA, suggesting the BOLD-MRI is more sensitive than ABPI for 
detecting incremental changes in lower limb perfusion. Having a patent SFA 
should results in a greater improvement in inflow into the calf and therefore one 
would expect the degree of improvement in perfusion to be greater, compared 
with cases where the SFA is occluded and calf perfusion is reliant on collateral 
flow distal to the revascularised proximal segment.   
Particularly in patients with CLI who have tissue loss, the adequacy of the 
revascularisation procedure and its effect on downstream perfusion may not 
become apparent until there is failure to heal several weeks after intervention, 
by which time the opportunity to re-intervene may have been lost, resulting in 
limb loss.  Rapid assessment of changes in perfusion may identify a group of 
patients where further revascularisation is warranted to enable a satisfactory 
outcome.   
5.5.3 BOLD-MRI Assessment to Identify the Need for Further Intervention 
The GRE BOLD-MRI sequence developed in this study has shown that it is 
sensitive to differences in perfusion in different groups, can identify changes in 
perfusion and can differentiate between incremental changes in perfusion.  The 
patients undergoing pre and post intervention imaging had successful 
outcomes.  What is needed to assess this technique further is investigating 
patients where the revascularisation has not been successful or adequate.  It 
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can be hypothesised that in these patients the improvements detected with 
BOLD-MRI can identify these shortcomings and inform management plans to 
include further revascularisation. 
With the advent of interventional MRI suites, it may even be possible to perform 
BOLD-MRI on table to identify those patients that require further procedures, 
which could then be performed immediately.  These combined operating and 
imaging suites are beginning to inform management plans in interventional 
cardiology182 and neuroradiology183.  It is conceivable that the use of these 
facilities could be extended to patients with PAD, where baseline BOLD-MRI is 
undertaken, a procedure performed followed by repeat imaging.  This may allow 
for immediate analysis of changes in perfusion to identify those cohorts of 
patients where further revascularisation is required, and this could be offered 
immediately.   
5.6 Summary 
This study has shown that the novel GRE BOLD-MRI sequence can reliably 
identify changes in perfusion after revascularisation.  It is also sensitive to the 
incremental nature of the inflow of blood the lower limb.  It can be envisaged 
that information gained from BOLD-MRI could help inform management 
decisions, and identify those patients where interventions are not sufficient to 
improve muscle perfusion.  With interventional MRI suites, these further 
procedures could be performed immediately without the need for patients to 
return to operating room. 
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CHAPTER 6 
Relating BOLD-MRI to Markers of Muscle 
Vascularity 
6.1 Introduction 
The basis of the signal generated in BOLD-MRI is dependent on the ratio of 
oxygenated and deoxygenated haemoglobin in tissue118,140,141.  Factors that 
alter this ratio therefore influence the BOLD signal generated.  Different 
physiological parameters have been postulated to influence skeletal muscle 
BOLD signal, such as blood flow, intravascular blood volume, cellular pH and 
fluid shifts, vessel diameter, and orientation140. However, it is generally 
accepted that the bulk of BOLD signal alterations in BOLD-MRI of skeletal 
muscle tissue is due to the delivery of oxygenated haemoglobin142,144,145,156, and 
therefore muscle perfusion. 
In cardiac perfusion imaging BOLD-MRI has been validated against PET126 and 
fractional flow reserve184 in man, and radiolabelled microspheres in animal 
models125 and shows good correlation.  In skeletal muscle, BOLD-MRI has 
been validated against TcPO2 and LDF showing a moderate to good 
correlation144.  Correlation is also seen with plethysmography and BOLD-
MRI139.  However, these are methods of assessing skin perfusion and global 
changes in the limb.   
 154 
In previous chapters we have described how novel GRE BOLD-MRI can 
differentiate between different groups and how intervention results in change in 
BOLD signal measured.  However ABPI, which is the most common measure 
for assessing perfusion in the limb, does not correlate with curve parameters.   
Histological endpoints can provide additional information regarding the status of 
perfusion in muscle.  Capillary:fibre (C:F) is an established technique for 
assessing perfusion in skeletal muscle185.  It has been shown that patients with 
PAD have a lower C:F ratio compared to age-matched controls186.  No previous 
attempts have been made to relate BOLD-MRI in skeletal muscle with such 
histological endpoints, and such comparison would provide further evidence 
that this technique can provide a valuable adjunct in the management of 
patients with PAD. 
6.2 Aims 
(i) To compare novel GRE BOLD-MRI derived curve parameters in patients 
undergoing major amputation with C:F ratio. 
6.3 Methods 
6.3.1 Study Participants 
Patients presenting with CLI with non-salvageable limbs requiring major 
amputation were recruited.  These patients did not undergo any intervention on 
the admission for major amputation, as recent revascularisation may have 
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influenced histology and BOLD-MRI derived endpoints.  Further details are 
described in chapter 2.2. 
6.3.2 Protocol for BOLD-MRI and Image Analysis 
All subjects underwent imaging using the MRI setup and cuffing protocol 
described in chapter 2.3 and 2.4.  The GRE sequence described in chapter 
3.3.2 was used and image analysis carried out as described in chapter 2.6 
using the automated analysis software.  The tibial tuberosity was used as an 
anatomical landmark and the distance from this to the middle of the imaging 
slice was measured.   
6.3.3 Muscle Biopsies at the time of Major Amputation Surgery 
At the time of major amputation, the level of the calf imaged with BOLD-MRI 
was marked using the tibial tuberosity as an anatomical landmark.  Prior to 
amputation, 1cm3 muscle biopsies were obtained from ischaemic muscle at 
level of imaging with BOLD-MRI, from the five muscle groups (anterior, lateral, 
soleus, gastrocnemius and deep posterior).  Biopsies (1cm3) were also obtained 
from better-perfused muscle, proximal to the amputation level.  From the 
proximal section, muscle biopsies were taken from the same five muscle groups 
in below knee amputations and biopsies taken from 3 muscle groups in above 
knee amputations (anterior, posterior, medial).   
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6.3.4 Immunohistochemical Staining for Capillary:Fibre Ratio 
Muscle biopsies were fixed in 4% paraformaldehyde for 30minutes and 
dehydrated in PBS/15% sucrose for 12hours, PBS/30% sucrose for 48hours 
and PBS/40% sucrose for a further 24hours.  Samples were dried, embedded in 
optimal cutting temperature compound (OCT, Sakura Finetek Inc., USA) and 
frozen in isopentane pre-cooled in liquid nitrogen.  Immunohistochemical 
staining was carried out using 7μm-thick frozen sections with the fluorescently 
labelled antibodies: primary endothelial cell marker (CD31, Alexa Fluor 488-
conjugated, 0.6mg/ml, Novus Biological, UK) and secondary basement 
membrane marker (laminin, Dylight 488-conjugated with Cy3 secondary, 
0.85mg/ml, Novus Biological, UK).   
Frozen slides were allowed to equilibrate at room temperature for 20 minutes. 
Tissue sections were then:  
1. Rehydrated with PBS for 5minutes 
2. Blocked in PBS containing 2.5mls FCS, 0.5g BSA, 50μl Triton x100 for 
1hour.  
3. Incubated with the primary antibody (1:100 in PBS containing 0.5mls 
FCS, 0.5g BSA) for 12hours.  
4. Washed in PBS 500mls with T2O 250μl 3 times.  
5. Incubated with the secondary antibody (1:200 in PBS containing 0.5mls 
FCS, 0.5g BSA) for 1hour.  
6. Washed in PBS 500mls with T2O 250μl 3 times.  
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7. Mounted with Vectashield mounting medium containing DAPI and a 
coverslip sealed with nail polish to prevent drying.  
Slides were visualised using a light microscope (Leitz, Leica, UK) and images 
captured using a mounted camera (EXi Blue, QImaging).  The C:F ratio was 
determined by analysis of 4 fields of view in 2 sections of each biopsy obtained 
5mm apart.  The mean was calculated from this for each muscle groups and 
used as the C:F ratio for that muscle. 
6.3.5 Statistical Analysis 
Statistical analysis was carried out using SPSS v20 (IBM Corp. Armonk, NY, 
USA) and Prism 5 (GraphPad Software Inc. California, USA).  Comparison of 
C:F ratio was made between biopsies from better perfused muscle proximal to 
the amputation site and those taken at the level of BOLD-MRI using an 
unpaired t-test.  For each patient the C:F ratio from poorly perfused muscle at 
the level of BOLD-MRI imaging was normalised with the C:F ratio from proximal 
better perfused muscle and correlated with Grad and SRi parameters, 
generated from the automated analysis software, using Spearman‟s correlation.  




6.4.1 Study Demographics 
3 CLI patients requiring primary major amputation were recruited (median age 
61years, range 36-77, 2 females), with 2 undergoing below knee amputations 
(BKA) and the other having an above knee amputation (AKA).  All 3 patients 
had undergone previous revascularisation attempts at limb salvage, but all had 
failed, with no intervention in the preceding 3months.  The 2 patients having a 
BKA were diabetics and the patient undergoing AKA was a smoker.  ABPI was 
not measurable in any of the amputation CLI patients. 
All 3 patients were able to tolerate BOLD-MRI with the cuffing protocol and all 
muscle groups were analysed.   
Muscle biopsies were harvested at the time of surgery, with tissue obtained 
from 5 muscle groups at the level of BOLD-MRI in the calf (n=15), and from 
proximal to the level of amputation (n=13, 5 muscle groups in BKA patients, and 
3 muscle groups in AKA patient)  
In all patients the amputation stumps healed primarily, with no secondary 
procedures required, meaning the perfusion to muscle in proximal to the 
amputation level was adequate. 
6.4.2 Capillary:Fibre Ratio in Ischaemic Lower Limb Muscle 
C:F ratio was measured as a histological marker of poor perfusion.  The ratio 
was compared between ischaemic muscle, at the level of BOLD-MRI, and 
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better-perfused muscle, proximal to the amputation level.  In the three patients 
who had amputations (one above knee and two below knee), both Grad (0.15 ± 
0.10ms/s) and SRi (7.74 ± 1.05%) fell outside the range for age-matched 
control limbs (Grad 0.38 ± 0.17ms/s and SRi 13.77 ± 6.33%, p<0.0005 for both, 
unpaired test), confirming impaired perfusion in the ischaemic limb at the level 
of BOLD-MRI (Figure 6.1).   
 
Figure 6.1:  Grad and SRi in CLI patients undergoing major limb amputation compared to 
age-matched controls (unpaired t-test). 
 
C:F ratio was compared in ischaemic muscle at the level of BOLD-MRI with 
ratios obtained from better-perfused muscle proximal to the level of amputation.  
A typical example of CD31 and laminin staining for C:F ratio is shown in Figure 
6.2.  Analysis of biopsies from well-perfused muscle proximal to the amputation 









































Figure 6.2:  Example of CD31 and Laminin co-staining to determine capillary:fibre ratio in 
muscle biopsies obtained from better-perfused muscle proximal to amputation level and 







Figure 6.3:  Capillary:fibre ratio between better-perfused proximal to amputation and 
ischaemic muscle at level of BOLD-MRI (unpaired t-test). 
 
6.4.3 Correlation of BOLD-MRI with Capillary:Fibre Ratio 
The C:F ratio in ischaemic muscle from each of the muscle groups in the calf 
was normalised to the C:F ratio in the proximal better-perfused muscle.  This 
allowed comparison of the difference in the C:F ratio between better-perfused 
and ischaemic muscle in each patient undergoing amputation, and this was 
correlated with the BOLD-MRI derived parameters of Grad and SRi.  There was 
a significant correlation between Grad and C:F ratio (r. 0.64, p < 0.01), but none 


















Figure 6.4:  Correlation of Grad (A) and SRi (B) in CLI patients undergoing major 
amputation with normalised capillary:fibre ratios (Spearman’s correlation) 
 
6.5 Discussion 
It is generally accepted that the signal generated in BOLD-MRI is mainly 
influenced by the ratio of oxygenated and deoxygenated haemoglobin in 
tissue118,140,141, however other factors are believed to contribute in skeletal 
muscle BOLD.  Validation of BOLD-MRI in skeletal muscle has concentrated on 
comparing it to methods such as TcPO2, LDF and VOP139,144, but these 
modalities are surrogate markers of muscle perfusion.  Furthermore, in previous 
chapters it has been demonstrated that although ABPI and BOLD-MRI do 
detect limb ischaemia, no correlation between the two has been found.  There 
has been no study to date investigating it with histological endpoints or other 
methods of assessing muscle perfusion directly, e.g. PET.  




































This study is the first to attempt to validate BOLD-MRI in skeletal muscle with a 
histological marker of perfusion.  Muscle imaged with the novel GRE BOLD-MRI 
sequence has been shown to be ischaemic compared to proximal muscle, as 
demonstrated by a significantly lower C:F ratio.  The proximal muscle was 
adequately perfused as demonstrated by stump healing in all patients 
undergoing major amputation.  The sequence we have used is only capable of 
imaging a single slice, as the processing power and hardware capability of coils 
do not permit imaging at multiple levels.  It was therefore not possible to image 
both levels from which muscle biopsies were obtained. Imaging to include both 
levels would have required repeat imaging, with placement of the imaging slice 
at each level.  The effects of consecutive scanning with repeat cuffing on 
perfusion imaging with BOLD-MRI is unknown, but an element of muscle 
perfusion adaptation may introduce errors in measurements.  The CLI patients 
underwent surgery fairly rapidly after the decision was made to amputate and 
therefore repeat imaging at separate sittings was not possible. 
C:F ratios measured in CLI patient were correlated with BOLD-MRI derived 
perfusion measures, Grad and SRi.  A correlation has been shown for Grad but 
not SRi.  This may suggest that Grad is a more sensitive marker of perfusion, 
and that reactive hyperaemia may be the more important aspect of using the 
cuffing arterial occlusion model to promote changes in perfusion.  It maybe that 
this aspect of the curve represents that muscles ability to adapt to an increase 
demand for perfusion, whereas the ischaemic portion represents the ability to 
tolerate low perfusion.  If you compare this to patients with IC, muscle pain 
occurs after exercise, representing the muscles ability to adapt, i.e. reactive 
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hyperaemia, whereas the ischaemic portion may represent the late changes 
that occur with CLI, i.e. rest pain representing low perfusion even at rest and 
therefore no ability to tolerate low perfusion.  The fact this occurs later, may 
mean that the changes in SRi are not as profound as with Grad. 
As a correlation between parameters obtained from BOLD-MRI and C:F, but no 
such association with ABPI has been demonstrated, it may also suggest that 
pressure derived measurements may represent an overall simplified view of 
perfusion in the limb.  The macrovascular inflow may influence the ABPI more, 
whereas in BOLD-MRI as it is the muscle that is being assessed, this may 
represent what is occurring at the microvascular level, including the impact of 
inflow into the tissue.  As the muscle represents the end organ that is poorly 
perfused in PAD, this measure may offer a more informative assessment of 
tissue dysfunction in patients with arterial disease.   
As the BOLD-MRI sequence was unable to scan at multiple levels this does 
highlight a limitation to the correlation seen.  Ideally we would correlate C:F 
ratios in the ischaemic muscle and better perfused proximal muscle with BOLD 
derived parameters at the respective levels.  This does limit the inference we 
can draw about the correlation seen in this chapter. 
6.6 Summary  
This is the first study to attempt to validate BOLD-MRI derived parameters with 
histological markers of muscle perfusion, rather than surrogates (e.g. TcPO2, 
LDF, VOP).  It has been shown that muscle imaged with BOLD-MRI is 
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ischaemic, with a lower C:F ratio compared to muscle better-perfused.  
Correlation of Grad with C:F ratios has also been demonstrated, suggesting that 










CHAPTER 7  
General Discussion and Future Work 
7.1 Discussion 
There is currently no reliable method for assessing muscle perfusion in the 
lower limb52. Techniques most commonly used include TcPO2, LDF and VOP, 
but these measure either skin perfusion or global changes in the limb.  It is 
estimated that under resting conditions up to 70% of blood flow to the limb is 
directed to skeletal muscle with the remainder supplying the skin58.  Skin 
perfusion has been shown to be maintained until the very late stages of 
PAD78,187, and may represent terminal changes in patients with PAD.  The most 
widely utilised technique for assessing the haemodynamic status of the limb in 
patients with PAD is ABPI.  This measurement, albeit a simple clinical test to 
perform, provides only a surrogate of tissue perfusion and is more a global 
indicator of flow in the major lower limb vessels.  
Patients with CLI exhibit the end stage of PAD, and as such are at high risk of 
morbidity and mortality1,3.  Revascularisation is the mainstay of treatment for 
these patients, but this can be complex, given the fact that disease often affects 
multiple segments of the lower limb vessels and the patients‟ comorbidities.  
Prompt, objective assessment of the intervention undertaken is vital to ensure 
adequate perfusion has been restored to achieve limb salvage.  Currently this is 
done with a combination of ABPI and assessment of clinical signs and 
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symptoms, but in patients with tissue loss, improvement in healing can take 
weeks and an opportunity to fully optimise perfusion maybe lost in that time177–
179. 
Medical conditions such as diabetes, an important cause of limb loss and 
functional disability, affects the microcirculation as well as the larger vessels188.  
Conventional imaging does not allow reliable assessment of the 
microcirculation, and could, therefore, underestimate the degree of functional 
limb ischaemia if the main vessels are patent. Similarly, the impact of the 
collateral circulation (an important compensatory mechanism for maintaining 
limb perfusion when the main vessels are occluded) cannot be quantified189. An 
accurate method for assessing the functional effect of collaterals on tissue 
perfusion would be invaluable for determining the efficacy of novel treatments 
such as angiogenic cell therapy42,190 that aim to promote collateralisation. 
The gold standard for measuring perfusion in skeletal muscle is PET imaging.  It 
allows for accurate mapping of perfusion with radiolabelled isotopes.  The cost 
and infrastructure required for PET imaging, however, make its widespread use 
prohibitive, and also exposes patients to ionising radiation. 
Imaging modalities such as MRI, that do not utilise ionising radiation and are 
capable of accurately measuring perfusion in muscle, hold promise in the 
assessment and management of patients with PAD.  Three main MRI 
techniques have been used in perfusion imaging; BOLD, ASL and DCE.  Unlike 
BOLD and ASL, DCE requires the administration of Gadolinium based contrast 
agents, with inherent risks of NSF in patients with chronic kidney disease.  
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The blood flow to muscle at rest is extremely low and therefore difficult to 
assess.  Studies using methods such as PET have estimated this to be in the 
region of 1-2.2ml/min/100g muscle54,55.  Therefore, techniques to measure 
skeletal muscle perfusion at rest need to be extremely sensitive to detect 
differences in patients with PAD.  To detect measurable changes in perfusion, 
manoeuvres to increase muscle blood flow, i.e. hyperaemia, are commonly 
employed.  The 3 most common methods used are, ischaemia to evoke 
reactive hyperaemia on restoration of blood flow, exercising to produce a 
functional hyperaemia, and vasodilators inducing a pharmacological 
hyperaemia.  Similar methods are used in cardiac perfusion imaging, where 
exercise and stress testing is utilised to evoke a hyperaemic response to 
assess perfusion.  This same analogy applies to skeletal muscle perfusion 
assessment. 
In this study we used the ischaemia-reactive hyperaemia model for a number of 
reasons.  This model provides the most reproducible and user independent 
method of increasing blood flow to muscle140,141.  It is independent of the 
subject been imaged and the same conditions can be replicated every time.  
This is particularly useful if the same subject undergoes repeat imaging, 
allowing for accurate comparison of perfusion.  In contrast, use of an exercise 
model would have required the use of MRI compatible ergometers. Moreover, it 
can be difficult for patients with PAD to exercise sufficiently and consistently to 
the same intensity each time perfusion is assessed. Exercising also increases 
motion in the limb, even after cessation, introducing artefacts on MRI.  
Pharmacological hyperaemia usually requires intra-arterial administration of 
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very short acting vasodilators, such as adenosine.  Intra-arterial cannulation is 
not without risk and would add considerable time required to complete the 
imaging. 
The cuffing protocol used in this study is a standard method using the 
ischaemia-reactive hyperaemia model, with baseline measurement followed by 
rapid cuff inflation to suprasystolic pressures.  This occludes the inflow to the 
limb and induces ischaemia.  The cuff inflation needs to be rapid in BOLD-MRI 
to minimise the influence of venous filling on T2* signal101.  The cuff remained 
inflated for 5minutes to adequately stress the muscle, and to maximise the 
reactive hyperaemia.  There is no consensus on how long the cuff needs to 
remain inflated.  Reactive hyperaemia was evoked by rapid cuff deflation 
allowing inflow in to the limb. 
By using reactive hyperaemia, with the same investigator inflating the cuff, the 
variability in hyperaemia was minimised, and therefore more reliable 
comparisons could be made. 
7.1.2 Non-Contrast MRI Techniques for Assessing Muscle Perfusion 
ASL and BOLD are the 2 non-contrast MRI techniques for assessing skeletal 
muscle perfusion.  ASL-MRI magnetically tags the water molecules in blood 
proximal to the region of interest and then measure the signal in tissue based in 
this labelling. With kinetic modelling it possible to quantify perfusion based on 
the magnetic signal detected in muscle.  BOLD-MRI uses the different magnetic 
properties of haemoglobin depending on it oxygenation status.  Deoxygenated 
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haemoglobin is paramagnetic, which results in an increase in localised 
magnetic field distortions leading to a lower signal on MRI, particularly T2* 
relaxation.  An increase in perfusion lowers the deoxygenated haemoglobin in 
tissue and therefore, and increase in T2* signal52. 
The present study compared the spatial resolution between ASL and BOLD 
MRI.  ASL requires rapid image acquisition, usually with an EPI sequence, to 
capture the magnetically tagged blood, which comes at the expense of spatial 
resolution.  An improved GRE sequence for BOLD-MRI has overcome this 
limitation of EPI sequences allowing for improved resolution.  During sequence 
development an ASL technique using pCASL was compared with the novel 
BOLD-MRI and the improved spatial resolution was confirmed.   
Spatial resolution is important in muscle perfusion studies to accurately 
excluded non-muscular tissue, such as bone, major blood vessels and soft 
tissue.  Inclusion of these structures introduces errors in assessing muscle 
perfusion.  The signal obtained is not a true reflection of what is occurring in 
muscle, but also includes artefact from these tissues. 
Also, as BOLD-MRI acquires the majority of its signal directly from the ratio of 
oxygenated and deoxygenated haemoglobin in the tissue, complex kinetic 
modelling is not required to determine perfusion.  This is also a potential source 
of error when assessing perfusion using ASL-MRI.  The argument levelled 
against BOLD-MRI is that it does not provide absolute quantification of 
perfusion, but as already eluded to, due to the low perfusion state of muscle at 
rest and wide variations seen with increased demand, the absolute perfusion 
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may be less important than the actual changes in perfusion seen after 
provoking hyperaemia52.   
The signal generated in ASL-MRI from magnetically tagged water molecules in 
blood is very small.  It is estimated the signal generated is only 0.5-1% over and 
above the background signal104, making detection of a reliable signal difficult.  
The better signal to noise ratio of BOLD-MRI, along with the factors discussed 
above, means it maybe superior to ASL-MRI. 
7.1.3 Novel GRE BOLD-MRI 
In this study a novel GRE method has been described to acquire BOLD-MRI 
images.  Traditionally an EPI sequence has been utilised to measure T2* signal 
due to the rapid acquisition this method allows142–144,154,157,160,163,164,166,168.  This 
is important to assess changes in perfusion with the different models that are 
used to evoke changes in muscle blood flow.  The limitation of EPI sequences 
is that an improvement in temporal resolution comes at the expense of spatial 
resolution, with the issues described with ASL-MRI above becoming a factor.   
The novel sequence used in the present study relies on a gradient echo method 
to acquire changes in T2* signal.  This results in improved spatial resolution.  
The improvement in scanner hardware and processing software allow for 
improved temporal resolution with images acquired every 3seconds.  These 
improvements also allow for an increase in the number of echoes that can be 
used to measure T2* relaxation resulting in more accurate quantification is 
decay.  This, coupled with imaging at higher magnetic field strengths (3T versus 
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1.5T) allows for more sensitive assessment of T2* signal changes with BOLD-
MRI.   
7.1.4 Reproducibility of BOLD-MRI 
Although BOLD-MRI has been used to assess perfusion in the lower limb a lack 
of reproducibility has been a weakness155.  The novel GRE sequence used in 
this study aims to overcome this by improving spatial and temporal resolution, 
increased sensitivity to T2* signal achieved with a higher number of echoes, 
and imaging at higher field strengths (3T).   
The GRE sequence used in the present study shows excellent intraclass 
correlation for both inter-user and inter-scan reproducibility.  The increased 
sensitivity of measuring T2* signal with this method has improved its 
reproducibility.  An automated software program was used to allow for ROI‟s to 
be drawn accurately within muscle compartments, making full use of the 
improved spatial resolution and allowing automated generation and analysis of 
signal intensity time course curves and T2* curve parameters. The automated 
nature allows for objective assessment of T2* signal changes, reducing 
operator dependent error and improving reproducibility159.  
7.1.5 T2* signature in the Ischaemic Limb 
Analysing the signal intensity time course curves obtained with BOLD-MRI 
reveals different perfusion profiles between different groups.  At baseline there 
is steady T2* signal until cuff inflation and arterial occlusion.  There is no 
difference between controls and patients with PAD/CLI.  The absolute value of 
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T2* signal at baseline varies between subjects, and even within subjects 
between interval scans, and direct comparison is meaningless.  For this reason 
T2* signal intensity time course curves were normalised to the baseline prior to 
cuff inflation to assess changes in T2* signal with cuff inflation and deflation and 
to allow meaningful comparison between subjects and between interval scans 
in the same subjects.   
With the onset of ischaemia induced by arterial occlusion, a fall in T2* signal is 
seen in all group‟s, however the controls see a greater decrease in signal 
compared with CLI patients with an early plateau.  Ischaemia results in a higher 
ratio of deoxygenated compared to oxygenated haemoglobin, and therefore a 
lower T2* signal.  This is consistent with previous studies in patients with 
PAD147.  This levelling off in T2* signal after cuffing in CLI patients may 
represent a reduced physiological reserve of muscle to ischaemic stress191.  
With the cuff deflation, reactive hyperaemia results and an increase in T2* 
signal is seen in all groups.  The influx of oxygenated haemoglobin results in 
washout of deoxygenated haemoglobin and therefore a higher T2* signal.  CLI 
patients have a slower rise in signal after cuff deflation compared to controls 
and again this consistent with previous reports in PAD subjects142,143,155.  This 
slower rise in signal may be due to less efficient delivery of oxygenated 
haemoglobin to muscle and slower washout of deoxygenated haemoglobin. 
Analysis of different parts of the T2* signal intensity time course curves results 
in curve parameters that can be used as a marker of perfusion. Previous 
studies have suggested that parameters such as TTP, T2*Max and THIM may 
represent the most discriminatory indicators of BOLD-MRI based perfusion 
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assessment142,143,147,155,164.  These parameters interrogate both the ischaemic 
and reactive hyperaemic parts of the signal intensity curve, however 
reproducibility of these parameters has never been shown. 
Using the automated analysis software program, two parameters (Grad and 
SRi) from the signal intensity time course curves were identified as being most 
informative in differentiating between CLI patients and controls.  The Grad can 
be thought of as analogous to TTP, but the reason for choosing gradient is that 
it can be reliably and objectively measured.  In some patients with CLI, the TTP 
is difficult to identify, as there is very little overshoot in reactive hyperaemia.  
With the automated analysis the gradient is calculated by taking the mean of 
the highest 10 readings of the first derivative during reactive hyperaemia.  This 
allows for a more standardised approach to analyse curve parameters, reducing 
inter user variability.  SRi is akin to THIM, assessing changes in T2* signal 
during the ischaemic phase.  SRi can, however, be more readily measured, as 
the percentage drop in signal is automatically analysed, whereas THIM requires 
the user to identify specific points in the T2* curve.  The analysis software 
developed does require manual selection of individual ROI‟s by the user. In 
future studies the reproducibility of our technique could be improved by using 
automated recognition of individual muscle compartments and exclusion of 
pixels from intra-muscular vessels which may introduce an element of error in 
T2* estimation in the muscle. 
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7.1.6 BOLD-MRI measurement of limb perfusion after successful 
revascularisation  
Successful revascularisation results in changes in both the ischaemic and 
reactive hyperaemic parts of the curve, with curve resembling those obtained 
from control limbs.  This is confirmed with improvement in curve parameters, 
with the values resembling those achieved from control limbs.  This shows that 
BOLD-MRI can detect measurable improvement in muscle perfusion after 
successful revascularisation. 
BOLD-MRI is also sensitive at detecting changes in perfusion related to the 
status of the inflow vessels.  Patients with a patent SFA post intervention have a 
significantly improved T2* gradient compared with patients in whom the SFA 
remains occluded.  A similar improvement is also seen in SRi, however this 
failed to reach significance.  The status of the inflow is important, particularly in 
patients with CLI.  These patients usually have multi level disease but in a 
significant proportion treating the disease in the more proximal vessels only is 
sufficient to resolve the symptoms. This is an advantage particularly when 
treating the full extent of multilevel disease can be a major undertaking in a 
patient population that is already has significant co-morbidities, which carries 
significant inherent risks of prolonged and complex procedure. 
The patients recruited to the present study all had resolution of their CLI after 
intervention, and therefore future studies should investigate patients with a high 
risk of intervention failure to determine if BOLD-MRI can reliably identify at an 
early stage those that require further intervention. The advent of hybrid 
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magnetic resonance (MR)/X-ray (XMR) interventional facilities would facilitate 
the use of BOLD-MRI as a means of immediately assessing changes in 
perfusion „on table‟.  This would inform the effects of incremental 
revascularisation on perfusion in the limb (considered as the end organ effect of 
restoring vessel patency) and determine the need for further intervention.  For 
example, in the case of a patient with both iliac and SFA disease, on table 
BOLD-MRI could demonstrate a need for incremental recanalization of the SFA 
even after successful iliac intervention.  Conversely, it may demonstrate that 
adequate improvement in perfusion had occurred with iliac revascularisation 
only. BOLD-MRI sequences could also readily be added to MR angiography 
studies to provide both functional and anatomical information simultaneously.  
This could be useful in planning interventions and assessing outcomes after 
revascularisation.   
7.1.7 Correlation and Validation of BOLD-MRI with Established Methods 
for Assessing Perfusion 
Limited studies have been performed in an attempt to validate BOLD-MRI in the 
lower limb.  To date these studies have used methods such as TcPO2 and LDF 
to show a good correlation with BOLD-MRI derived parameters144,154,192.  A 
reasonable correlation has also been shown with perfusion measured with ASL-
MRI101.  Histological correlation of muscle vascularity with perfusion determined 
by modalities such as PET have not been performed in the lower limb.   
Perfusion assessment with BOLD-MRI in the heart has been validated against 
more robust endpoints121.  BOLD-MRI has been compared with radiolabelled 
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microspheres in animal models, showing good correlation124.  In human studies, 
BOLD-MRI has been correlated with established techniques of assessing 
coronary artery haemodynamics and cardiac muscle perfusion.  When 
compared against coronary angiography, a significantly lower signal is detected 
with BOLD-MRI in myocardial segments perfused by coronary arteries with 
significant stenosis compared with myocardium supplied by non-stenosed 
vessels123,127,193.  BOLD-MRI also compares favourably with gadolinium 
enhanced MRI194 and SPECT imaging123.  More recently, fractional flow reserve 
(FFR) has been correlated with BOLD-MRI184.  FFR uses specialised wires with 
pressure sensors at the tip to measure the pressure changes across a stenosis 
in the coronary circulation.  This provides a ratio, which has been shown to be 
predictive for detecting significant coronary artery lesion (FFR<0.75-0.8) 
requiring intervention195.  BOLD-MRI signal has been shown to be significantly 
lower in myocardium supplied by coronary arteries with an FFR<0.8, compared 
to myocardium supplied by arteries with a FFR>0.8.  Perhaps the gold standard 
imaging technique to measure myocardial perfusion remains PET, and it has 
shown that BOLD-MRI compares favourably with PET122. 
The present study included efforts to correlate BOLD-MRI in the lower limb with 
histological endpoints.  In CLI patients undergoing major limb amputation, 
BOLD-MRI was performed prior to surgery and parameters were correlated to 
capillary:fibre ratio (a measure of tissue vascularity) obtained from muscle 
biopsy taking at the time of surgery from the imaging slice.  Grad showed a 
good correlation with C:F ratio. This is the first attempt to validate BOLD-MRI in 
the lower limb with a marker of vascularity, and therefore of perfusion.   
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7.2 Limitations 
A limitation of BOLD-MRI is its utility in patients undergoing distal bypass, 
where oedema and haematoma in the field of view may preclude accurate 
assessment of T2* signal in muscle.  In addition the use of thigh cuff to induce 
ischaemia and evoke reactive hyperaemia would result in temporary occlusion 
of the bypass graft, with a theoretical risk of precipitating graft occlusion. 
All subjects imaged before and after revascularisation had successful 
intervention with improvement in symptoms.  This improvement was reflected in 
the BOLD-MRI derived parameters.  To investigate the predictive potential of 
BOLD-MRI in assessing whether intervention is sufficient to allow for adequate 
muscle perfusion ideally imaging needs to be performed in a cohort of patients 
where revascularisation is not sufficient.  Correlation with BOLD derived 
perfusion parameters with outcomes would allow for this to be investigated.  
Not all CLI patients were able to remain still for the duration of the BOLD-MRI 
due to the presence of rest pain when supine.  Although dynamic imaging was 
relatively rapid, taking only 12minutes, some patients did not tolerate the scan.  
The effects of haemodilution and haematocrit are known to show a linear 
response to T2* signal in BOLD MRI196–198, but the effects of conditions such as 
congestive cardiac failure and severe aortic stenosis where there is an impact 
on cardiac output is less known.  This may have an influence on the T2* signal, 
but more work is required to fully evaluate the impact on BOLD-MRI. 
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Previous studies have shown a correlation of BOLD-MRI with other markers of 
perfusion such as LDI and TcPO2144,154,192, this study only used ABPI as a 
marker of perfusion and failed to show any correlation.  Validation of BOLD-MRI 
could have been strengthened if other markers of perfusion such as toe 
pressures or near-infrared spectroscopy had shown a correlation. 
 
7.3 Future Work 
This study has shown the utility of BOLD-MRI in assessing perfusion and its 
sensitivity to changes in perfusion.  Correlation with histological endpoints in 
this study has assisted in confirming this.  Further validation maybe warranted 
with comparison with radiolabelled microspheres in animal models, and with 
PET imaging in human studies.   
A reliable method for assessing segmental muscle perfusion in the limb could 
aid the diagnosis and planning of interventions in patients with PAD. It would 
also facilitate rapid assessment of changes in perfusion to determine the 
adequacy of revascularisation procedures. This strategy could ultimately 
improve limb salvage in CLI patients and therefore, it maybe that BOLD-MRI 
merits further investigation in a clinical trial.  This study has assessed the 
immediate changes in perfusion measured with BOLD-MRI in patients 
undergoing successful revascularisation.  A study in a much larger cohort would 
allow measurement of BOLD derived parameters of perfusion in patients where 
intervention has not been successful.  It may allow determination if BOLD-MRI 
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can predict whether revascularisation is sufficient or whether further intervention 
is warranted to improve clinical outcomes e.g. limb salvage.  Furthermore, to 
assess adequacy of revascularisation a randomised controlled trial where 
patients undergo standard, currently accepted intervention could be compared 
to a group that undergo maximal revascularisation and BOLD measurements 
correlated with clinical outcome.  Such trials would be needed before BOLD-
MRI can be fully accepted as a reliable measure of muscle perfusion. 
Development of medical angiogenic therapies requires a method for identifying 
areas of poor perfusion as a target, and also to be able monitor the progress of 
the therapy.  BOLD-MRI maybe able to fulfil this role for future studies in novel 
angiogenic therapies.  The highly reproducible and sensitive measures derived 
from BOLD-MRI suggest this method could meet the requirements for studies in 
this area.  BOLD-MRI could also be combined with high-resolution contrast 
enhanced MRI sequences to accurately delineate and quantify collaterals 
formation.  This could be correlated with improvements in perfusion and clinical 
outcomes.   
This study was performed on a 3T MRI scanner that is readily available for 
clinical use.  Newer scanners have been developed with higher magnetic field 
strengths (4.5T, 7T and 9.4T) are now becoming available in the research field 
which would be more sensitive to changes in BOLD signal.  These scanners 
may improve the accuracy of BOLD-MRI further.  This coupled with improved 
processing capabilities allowing for more complex MRI sequences would 
undoubtedly improve the sensitivity and accuracy of BOLD-MRI.  
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7.4 Summary  
Tissue perfusion, rather than the anatomical extent of disease affecting the 
main vessels, determines the severity of ischaemia in the lower limb. BOLD-
MRI can measure perfusion in the calf musculature with a high degree of 
accuracy and reproducibility and is sensitive to changes in perfusion after limb 
revascularisation.  This technique could be combined with standard MRI 
angiography to provide functional as well as anatomical imaging. 
The present study shows that BOLD-MRI consistently detects perfusion deficits 
in the ischaemic limb and quantifies improvements in perfusion after 
revascularisation.  A reliable method for assessing segmental muscle perfusion 
in the limb would facilitate rapid detection of changes in perfusion to determine 
the adequacy of revascularisation procedures.  BOLD based perfusion metrics 
may also allow assessment of pharmacologic and cell based angiogenic 
therapies being tested as part of clinical studies and merits further investigation 








































%% READS IN A SERIES OF DICOM IMAGES                                     
%% 
%% CREATES AND SAVES OR LOADS IN SAVED MASK ROIS                         
%% 
%% PLOTS TIME COURSES OF THE ROIS                                        
%% 
%% Written by Wesolek (Roman Wesolowski)                                 
%% 





%% Name and path of outcoming and incoming files 
%path='/Volumes/DOCS/DATA/studies/'; 
%cd(path) 
ROIcheck=input('Have you saved ROIs to use in this subject? [y/n]: 
','s'); 
ROIcorr=input('Would you like to redo any of the ROIs? [y/n]: ','s'); 
  
[FileName,PathName] = uigetfile({'*','*'},'Input the first DICOM 













    im4D_info_=dicominfo(strcat(PathName,name_dir(i).name)); 
    im4D_info_.BitsAllocated=32; 
    im4D(:,:,:,i)=im4D_info_.RescaleSlope*dicomread(im4D_info_); 
    waitbar(i/dyns,h,strcat('Loading Files... 
',num2str(round(i/dyns*100)),' %')); 
%    fprintf(1,'File Name: %s \n',name_dir(i).name); %prints out all 
the names of loaded files 
end 
close(h) 




    [FileNameA,PathNameA] = uigetfile({'*','*'},'Input the first DICOM 
anatomical image (exported from Osirix)'); 
    imAnat_info=dicominfo(strcat(PathNameA,FileNameA)); 
    suffix=strfind(FileNameA,'.'); 
    FileNameA=FileNameA(1:suffix(1)-5); 
    dyns=imAnat_info.NumberOfTemporalPositions; 
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    if (dyns==1) 
        h=waitbar(0,'Loading Files...'); 
        slc=imAnat_info.Private_2001_1018; 
        name_dir1=dir(strcat(PathNameA,FileNameA,'*')); 
        name_dir1=name_dir1(1:slc); 
        datefile=num2str(char({name_dir1.name})); 
        for i=1:slc 
            
imAnat(:,:,i)=dicomread(strcat(PathNameA,name_dir1(i).name)); 
%            fprintf(1,'File Name: %s \n',name_dir1(i).name); 
            waitbar(i/slc,h,strcat('Loading Files... 
',num2str(round(i/slc*100)),' %')); 
        end 
        close(h) 
        fprintf(1,'Total of %d anatomical files loaded \n',i); 
    else 
        name_dir1=dir(strcat(PathName,FileName,'*')); 
        name_dir1=name_dir1(1:dyns); 
        datefile=num2str(char({name_dir1.name})); 
        h=waitbar(0,'Loading Files...'); 
        for i=1:dyns 
            
imAnat(:,:,:,i)=dicomread(strcat(PathNameA,name_dir1(i).name)); 
            waitbar(i/dyns,h,strcat('Loading Files... 
',num2str(round(i/dyns*100)),' %')); 
%            fprintf(1,'File Name: %s \n',name_dir1(i).name); 
        end 
        close(h) 
        fprintf(1,'Total of %d anatomical files loaded \n',i); 
    end 
    figure(2) 
    clims=[0 500]; 
    imagesc(imAnat(:,:,ceil(end/2),ceil(end/2)),clims); 
    title('Anatomical Image') 
    colormap(gray) 
    k=0; 
    check='y'; 
    cd ..; mkdir('ROIs'); cd('ROIs'); 
    info_out=im4D_info_; 
    info_out.SeriesNumber=9901; 
    info_out.AcquisitionNumber=99; 
    info_out.SeriesDescription='ROIs'; 
    info_out.NumberOfTemporalPositions=1; 
    info_out.Private_2001_1081=1; 
    info_out.Private_2001_1082=1; 
    info_out.EchoTrainLength=1; 
    info_out.BitDepth=1; 
    info_out.BitsAllocated=1; 
    info_out.BitsStored=1; 
    info_out.HighBit=1; 
    info_out.RescaleSlope=1; 
    info_out.Private_2005_140a=1; 
%    
mask_all=zeros([size(im4D,1),size(im4D,2),size(im4D,3),size(im4D,4)]); 
    while (check~='n') 
        mask=zeros([size(im4D,1),size(im4D,2),1]); 
        if ROIcorr=='y' 
            k=input('Which ROI (specific number) would you like to 
correct? '); 
        else 
            k=k+1; 
        end 
        info_out.InstanceNumber=k; 
        disp('double-click on the ROI when finished...'); 
        figure(1) 
        image(im4D(:,:,ceil(end/2),1)); 
        title('Functional Image 1') 
        ROI=impoly(gca); 
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        roi=wait(ROI); 
%        roi=round(roi); 
        mask(:,:,1) = roipoly(mask(:,:),roi(:,1),roi(:,2)); 
        figure(2) 
        commandwindow 
        ROI_size=size(mask(mask>0),1); 
        fprintf(1,'Current ROI size is %i voxels \n',ROI_size); 
%         figure(10) 
%         imagesc(mask); 
%         mask=round(imresize(mask,[size(im4D,1) size(im4D,2)])); 
%         figure(11) 
%         imagesc(mask); 
        if (size(im4D,3)>1) 
            propagate = input('Propagate across slices? [y/n]: ','s'); 
            if (propagate=='y') 
                mask = repmat(mask,[1,1,size(im4D,3)]); 
            end 
        end         
        prop_dyn=input('Propagate across all the dynamics? [y/n]: 
','s'); 
        if (prop_dyn~='y') 
            prop=input('Provide number of dynamics to propagate this 
ROI to: '); 
            mask_ = repmat(mask,[1,1,1,prop-1]); 
            mask=cat(4,mask,mask_); 
            prop_num=1; 
            while 
(prop_num<size(im4D,4))%(prop_int~='n')&&(prop_num<size(im4D,4))) 
                prop=size(mask,4); 
                figure(1) 
                image(im4D(:,:,:,prop+1)) 
                ROI=impoly(gca,roi); 
                image_title=strcat('Functional Image 
',num2str(prop+1)); 
                title(image_title) 
                fprintf(1,'Double click on the ROI to accept its new 
position and shape \n'); 
                roi=wait(ROI); 
%                roi=round(roi); 
                mask_=zeros([size(im4D,1),size(im4D,2),1,1]); 
                figure(2) 
                commandwindow 
                mask_(:,:,1,1) = 
roipoly(mask_(:,:),roi(:,1),roi(:,2)); 
                ROI_size=size(mask_(mask_>0),1); 
                fprintf(1,'Current ROI size is %i voxels 
\n',ROI_size); 
                if ((size(im4D,3)>1)&propagate=='y') 
                    mask_=repmat(mask_,[1,1,size(im4D,3),1]); 
                end 
  
                prop_num=input('Provide number of dynamics to 
propagate this ROI to: '); 
                if (prop_num>size(im4D,4)) 
                    prop_num=size(im4D,4); 
                    fprintf(1,'Total number of functional scan has 
been exceeded.\n The ROIs will only by saved to match %i dynamics 
\n',prop_num); 
                end 
                prop=-prop+prop_num; 
                mask_ = repmat(mask_,[1,1,1,prop]); 
                mask=cat(4,mask,mask_); 
            end 
        else 
            mask = repmat(mask,[1,1,1,size(im4D,4)]); 
        end 
        check=input('Do you want to create/correct another ROI? [y/n]: 
','s'); 
 189 
        if k<10 
            suffix=strcat('0',num2str(k)); 
        else 
            suffix=num2str(k); 
        end 
        info_out.Filename=strcat(pwd,'/ROI_',suffix); 
        h=waitbar(0,'Saving Files...'); 
        for t=1:size(mask,4) 
            if (t<10) 
                
dicomwrite(mask(:,:,:,t),strcat('ROI_',suffix,'_dyn_00',num2str(t),'.d
cm'),info_out,'ObjectType','MR Image Storage'); 
            elseif (t<100) 
                
dicomwrite(mask(:,:,:,t),strcat('ROI_',suffix,'_dyn_0',num2str(t),'.dc
m'),info_out,'ObjectType','MR Image Storage'); 
            else 
                
dicomwrite(mask(:,:,:,t),strcat('ROI_',suffix,'_dyn_',num2str(t),'.dcm
'),info_out,'ObjectType','MR Image Storage'); 
            end 
            waitbar(t/size(mask,4),h,strcat('Saving Files... 
',num2str(round(t/size(mask,4)*100)),' %')); 
        end 
        close(h) 
        fprintf(1,'Total of %d ROI files saved \n',t); 
%        mask_all=mask_all+mask; 
%        mask=repmat(mask,[1 1 1 size(im4D,4)]); 
        
masked_im(:,k)=squeeze(sum(sum((im4D.*mask),1),2))./squeeze(sum(sum((i
m4D.*mask)~=0,1),2)); 
        figure(3) 
        if (k<6) 
            plot(0:3:(3*size(im4D,4)-
3),masked_im(:,k),colour_map(k),'LineWidth',1.5); 
        else 
            plot(0:3:(3*size(im4D,4)-3),masked_im(:,k),strcat('--
',colour_map(k)),'LineWidth',1.5); 
        end 
        lgnd(k,:)=strcat('ROI',suffix); 
        hold on 
    end 
else 
    [PathName] = uigetdir('','Input the folder containing previosuly 
saved ROI files'); 
    cd(PathName) 
    dir_data=dir; dir_index=[dir_data.isdir]; 
    name_dir=dir_data(~dir_index); 
    if (regexp('.DS_Store',name_dir(1).name)==1) 
        name_dir=name_dir(2:end); 
    end 
    ROIin_info=dicominfo(strcat(PathName,'/',name_dir(1).name)); 
%    mask_all=zeros([size(im4D,1),size(im4D,2),1,1]); 
    ROI_mask = 
zeros([size(im4D,1),size(im4D,2),size(im4D,3),size(name_dir,1)/size(im
4D,4)]); 
    h=waitbar(0,'Loading ROI Files...'); 
    for p=1:size(name_dir,1) 
        ROI_in = strcat(PathName,'/',name_dir(p).name); 
        ROI_mask(:,:,:,p) = 
(dicomread(ROI_in)>0);%/ROIin_info.LargestImagePixelValue; 
        waitbar(p/size(name_dir,1),h,strcat('Loading ROI Files... 
',num2str(round(p/size(name_dir,1)*100)),' %')); 
    end 
    close(h) 
    fprintf(1,'Total of %d ROI files loaded \n',p); 





    for k=1:size(mask,5) 
        if k<10 
            suffix=strcat('0',num2str(k)); 
        else 
            suffix=num2str(k); 
        end 
        
masked_im(:,k)=squeeze(sum(sum((im4D.*mask(:,:,:,:,k)),1),2))./squeeze
(sum(sum((im4D.*mask(:,:,:,:,k))~=0,1),2)); 
        figure(3) 
        if (k<6) 
            plot(0:3:(3*size(im4D,4)-
3),masked_im(:,k),colour_map(k),'LineWidth',1.5); 
        else 
            plot(0:3:(3*size(im4D,4)-3),masked_im(:,k),strcat('--
',colour_map(k)),'LineWidth',1.5); 
        end 
        lgnd(k,:)=strcat('ROI',suffix); 
        hold on         
















    masked_im_sm1(:,p)=smooth(masked_im(:,p),'moving'); 
    masked_im_sm10(:,p)=smooth(masked_im(:,p),10,'moving'); 




    figure(4) 
    if (k<6) 
        plot(0:3:(3*size(im4D,4)-
3),masked_im_sm1(:,k),colour_map(k),'LineWidth',1.5); 
    else 
        plot(0:3:(3*size(im4D,4)-3),masked_im_sm1(:,k),strcat('--
',colour_map(k)),'LineWidth',1.5); 
    end 
    hold on 
  
    figure(5) 
    if (k<6) 
        plot(0:3:(3*size(im4D,4)-
3),masked_im_sm10(:,k),colour_map(k),'LineWidth',1.5); 
    else 
        plot(0:3:(3*size(im4D,4)-3),masked_im_sm10(:,k),strcat('--
',colour_map(k)),'LineWidth',1.5); 
    end 
    hold on 
  
    figure(6) 
    if (k<6) 
        plot(0:3:(3*size(im4D,4)-
3),masked_im_sm20(:,k),colour_map(k),'LineWidth',1.5); 
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    else 
        plot(0:3:(3*size(im4D,4)-3),masked_im_sm20(:,k),strcat('--
',colour_map(k)),'LineWidth',1.5); 
    end 
    hold on 
end 
figure(4) 
    legend(lgnd); 
    xlabel('time [s]'); 
    ylabel('T_2*'); 
    title('Time course of T_2* changes for given ROIs'); 
    saveas(gcf,'allROIs_sm1.pdf','pdf'); 
    saveas(gcf,'allROIs_sm1.fig'); 
figure(5) 
    legend(lgnd); 
    xlabel('time [s]'); 
    ylabel('T_2*'); 
    title('Time course of T_2* changes for given ROIs'); 
    hold off 
    saveas(gcf,'allROIs_sm10.pdf','pdf'); 
    saveas(gcf,'allROIs_sm10.fig'); 
figure(6) 
    legend(lgnd); 
    xlabel('time [s]'); 
    ylabel('T_2*'); 
    title('Time course of T_2* changes for given ROIs'); 
    hold off 
    saveas(gcf,'allROIs_sm20.pdf','pdf'); 
    saveas(gcf,'allROIs_sm20.fig'); 
















    [c,peak_at_]=findpeaks(masked_im_sm10(143:end,a)); 
    peak_at_=peak_at_+142; 
    peak_val(a)=masked_im_sm10(peak_at_(1),a); 









    fprintf(1,'Curve analysis for ROI %i \n Baseline \t %.2f[ms] \n 
Baseline-End \t %.2f[ms] \n Dip Value \t %.2f[ms] \n Dip Position \t 
%i[s] \n Drop \t\t %.2f[%%] \n Peak Value \t %.2f[ms] \n Peak Position 
\t %i[s] \n Mean Gradient \t %.2f[ms/s] \n Time to half-dip %i[s] 
\n',p,baseline(p),baseline_rtn(p),dip_val(p),dip_at(p),drop(p),peak_va
l(p),peak_at(p),max_grad(p),time_to_half_dip(p)); 
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